Protocol Title: Multinational r andomized controlled cross-over trial 
comparing C-Brace to conv entional knee ankle foot 
orthoses with respect to balance, fall risk and activities of daily living. 
Study ID: [REMOVED] 
Document Date (version 7):   July 16, 2021 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 1 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29  
 
 
Clinical Investigation Plan (CIP)  
 
Multinational randomized co ntrolled cross -over trial comparing C -
Brace  to conventional knee ankle foot orthoses with respect to ba l-
ance, fall risk and activities of daily livi ng. 
 
CONFIDENTIAL DOCUMENT  
Document No. PS00120016A -001  
 
REVISION RECORD  
Vers. N o. Description  Valid from  
1.0 Creation of the clinical investigation plan  Signed release  
2.0 Changes include minor changes to inclusion/exclusion crite-
ria, addition of a sec ond baseline to the study schedule, addi-
tion of US study sites, and other minor change for clarity.  Signed release  
3.0 Changes include changes to the statistical  analysis descrip-
tion and other minor changes for clarity  Signed release  
4.0 Changes to addre ss risks and effects of the COVID -19 pan-
demic including updated study timeline, adaptations to the 
study procedure (7.3.12), updated study flow chart (7.4), updated risk -benefit assessment (11), and COVID -19 Risk 
Factors Assessment and patient re -consent ( 17.3).  Signed release  
5.0 Inclusion of Austria as new participating country , updated 
study flowchart   Signed release  Prepared by  Name / Function  
 
Dr. Marten Jakob  
Director Clinical Research and Services Duderstadt Date  
 
See digital signature  Signature  
 
 
 
 
Approved 
and r eleased 
by Name / Function  
 Dr. Andreas Hahn  
Corporate Vice President  Clinical 
Research and Services  
 Date  
 
See digital signature  Signature  
 
 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 2 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 REVISION RECORD  
Vers. N o. Description  Valid from  
6.0 Changes to the statistical analysis  and other minor changes 
for clarity . Moved  primary safety endpoint  to a secondary 
endpoint.  Remove d adaptive study design  and amended 
planned int erim analysis.  Signed release  
7.0 Updated enrollment number to account for screen failures 
and to reflect expansion to allow additional enrollments . Signed release  
 
Sponsor     
Otto Bock Healthcare Products G mbH  
Brehmstrasse 16  
1110 Wien  
 
Clinical Project Manager  
Dr. Marten Jakob  
Director Clinical Research and Services  
Otto bock SE & Co. KGaA  
Max -Näder Straße 15  
37115 Duderstadt  
Deutschland  
marten. jakob @ottobock.com  
 
 Coordinating Investigator  
Prof. Dr. med.  Frank Braatz  
Professor for Orthobionic  
Facharzt für Orthopädie und Unfallchirurgie, Physikalisch e und Rehabilitative Medizin  
Zentrum für Healthcare Technology der Privaten H ochschul e Göttingen  
Weender Landstraße 3- 7  
37073 Göttingen  
Deutschland  
 
Inve stigat ional Site 1  
Zentrum für Healthcare Technology der Privaten H ochschule Göttingen  
Weender Landstraße 3- 7  
37073 Göttingen  
Deutschland  
 
Principal Investigator    
Prof. Dr. med. Fr ank Braatz  
Professor for Orthobionic  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 3 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Facharzt für Orthopädie und Unfa llchir urgie, Physikalische  und Rehabilitative Medizin  
 
 
 
Investigational Site 2 
Katholisches Klinikum Koblenz -Montabaur  
Kardinal -Krementz -Str. 1-5 
56073 Koblenz  
 
Principal Investigator  
Dr. med. Axel Ruetz  
Facharzt für Orthopädie und Unfallchirurgie  
 
Inves tigat ional Site 3 
Adelante Kenniscentrum  
Zandbergsweg 111 
6432 CC Hoensbroek  
 
Principal Investigator  
Dr. Bea Hemmen  
Rehabilitation specialist  
 
Investigational Site 4  
Universitätskliniku m Heidelberg  
Zentrum für Orthopädie, Unfallchirurgie und  Paraplegi ologi e 
Schlierbacher Landstraße 200a  
69118 Heidelberg  
 
Principal Investigator  
PD Dr. Rüdiger Rupp  
 
Investigational Site 5  
Scheck & Siress  
2835 N Sheffield, Ste 301 Chicago, IL 60657  
Principal Investigator  
Jason Wening, CPO, FAAOP  
 
Investigational Site 6  
Hange r Clinic  
11155 South Main Street  
Houston, TX 77025  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 4 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator  
Tom DiBello, LO, CO, FAAOP  
Investigational Site 7  
Hanger Clinic Florida  
5432 Bee Ridge Road  
Sarasota, FL 34233  
 
Principal Investigator  
Chris Toelle, LCO, ACM  
 
Investigational Site 8  
Hanger Clinic  
4518 51st. Ave SW  
Seattle, WA 98116 
 
Principal Investigator  
Eric Weber , LCPO, FAAOP  
 
Investigational Site 9 
Orthopädisches Spital Speising  
Speisingerstraße 109  
AT-1130 Wien  
 
Principal Investigator  
Dr. Alexander Krebs  
 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 5 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Signature sheet  
 
 
Spo nsor  
 
 
 
______________________________________________________________  
Place , Date ,  Dr. Andreas Hahn  
 
 
 
______________________________________________________________  
Place, Date,   Dr. Marten Jakob  
 
  
Coordinating Investigator (if multicenter)  
  
 
 
______________________________________________________________  
Place , Date , Prof. Frank Braatz  
  
 
   
 
   
 
  
 
  
 
 
 
Principal Investigator  Site 1  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 6 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29  
  
______________________________________________________________  
Place, Date,  Prof. Frank Braatz  
  
Investigator  / Co-inve stigator  Site 1  
 
 
 
______________________________________________________________  
Place, Date,  Dr. Jennifer Ernst  
 
 
Investigator / Co -investigator  Site 1  
 
 
 
______________________________________________________________  
Place, Date,  Heiko Drewi tz 
  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 7 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Prin cipal Investigator  Site 2  
 
  
______________________________________________________________  
Place, Date,  Dr. Axel Ruetz  
  
Investigator / Co -investigator  Site 2  
 
 
 
______________________________________________________________  
Place, Date,  Rando lf Comtess e 
  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 8 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator  Site 3  
 
  
______________________________________________________________  
Place, Date,  Dr. Bea Hemmen  
  
Investigator / Co -investigator Site 3 
 
 
 
______________________________________________________________  
Place, Dat e, Sig natu re  
  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 9 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator  Site 4  
 
  
______________________________________________________________  
Place, Date,  PD Dr. Rüdiger Rupp  
  
 
 
 
Investigator / Co -inves tigator Site 4  
 
 
 
______________________________________________________________  
Place,  Date,  Dr. Cornelia Hensel   
   
 
 
Investigator / Co -investigator Site 4  
 
 
 
______________________________________________________________  
Place, Date,  Dr. Steffen Franz   
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 10 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator  Site 5  
 
  
__________________________________________________ ____ ________  
Place, Date,  Jason Wening  
  
Investigator / Co -investigator Site 5  
 
 
 
______________________________________________________________  
Place, Date,  Signature  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 11 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator Site 6  
 
  
__________________________________________ ____________________ 
Place, Date,  Tom DiBello  
  
Investigator / Co -investigator Site 6  
 
 
 
______________________________________________________________  
Place, Date, Signatur e  
 
  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 12 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator Site 7  
 
  
______________________________________________________________  
Place, Date,  Chris Toelle  
  
Investigator / Co -investigator Site 7  
 
 
 
______________________________________________________________  
Place, Date, Signat ure  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 13 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator Site 8  
 
  
______________________________________________________________  
Plac e, Date,  Eric We ber 
  
Investigator / Co -investigator Site 8  
 
 
 
______________________________________________________________  
Place, Date, Signatur e  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 14 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Principal Investigator  Site 9 
 
  
______________________________________________________________  
Place, Da te,   Dr. Alexander Krebs  
 
 
Investigator / Co -investigator Site 9 
 
 
 
______________________________________________________________  
Place, Date,   Dr. Andreas Kranzl  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 15 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29  Table of C ontents  
 
1 Study Ove rview  18 
2 Abbreviations  22 
3 Background 23 
4 Rationa le 25 
5 Investigational Device Information  25 
5.1 Manufacturer  25 
5.2 Description of the investigational device  26 
5.2.1  Technical description of mpKnee j oint 28 
5.3 Necessary training and experience to use the investigational  30 
device (C -Brace)  30 
5.3.1  Orthopaedic technician  30 
5.3.2  Patient  30 
5.4 Comparator Devices  31 
5.5 Accommodation to the devices  31 
5.6 Specific medical or surgical procedure involved  31 
5.7 Receip t, distribution and usage  31 
6 Study objectives and hypotheses  31 
6.1 Objectives  31 
6.1.1  Primary objective  31 
6.1.2  Secondary objectives  32 
6.1.3  Endpoints  32 
6.2 Hypothesis  32 
7 Study de sign 33 
7.1 Experimental plan  33 
7.2 Measures taken to minimize bias  33 
7.3 Study visit s and procedures  33 
7.3.1  Patient  enrollment  33 
7.3.2  Screening  and baseline procedure s 34 
7.3.3  Randomization 35 
7.3.4  Fitting  and Accom modation  36 
7.3.5  Home use (both arms) / Follow -up phone calls  37 
7.3.6  Study visit 1  37 
7.3.7  Cross –over process  39 
7.3.8  Wash out phase  39 
7.3.9  Study visit 2  39 
7.3.10  Patient´s C -Brace use after study end  39 
7.3.11  Transfer of patients to C -Brace registry for long term follow up  39 
7.3.12  Adaptations to the study procedure due to the COVID -19 pandemic  40 
8 Outcomes measures  42 
8.1 General data co llection  42 
8.2 Outcome measures  42 
8.2.1  Primary study objective  42 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 16 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 8.2.2  Secondary study objectives  43 
8.3 Study schedule  50 
9 Patient population  51 
9.1 Number of patients to enroll  51 
9.2 Duration individual patient’s participation  51 
9.3 Inclusion and Exclusion Criter ia: 51 
9.3.1  Inclus ion criteria  51 
9.3.2  Exclusion criteria  52 
9.3.3  Drop out or early termination of the study  53 
10 Statistics  53 
10.1  Sample size calculation  53 
10.1.1  Primary efficacy endpoint  54 
10.1. 2 Secondary endpoints  54 
10.2  Management of missing, unused or spur ious data  55 
10.3  Planned statistical analysis  56 
10.3.1  General patient and orthosis use data  57 
10.3.2  Primary efficacy outcome  57 
10.3.1  Secondary outcome analysis  58 
10.3.2  Randomization procedure  58 
10.4  Interim anal ysis 58 
11 Risk and benefit of the investigation device and clinical investigation 60 
12 Management of adverse events  63 
12.1  Description of possible adverse events & adverse device effects  63 
12.2  Definitions  63 
12.2.1  Additional national definitions  64 
12.3  Documentation of Adverse Events / Serious Adverse Event s 65 
12.4  Reporting of Adverse Events / Adverse Device Effects  65 
12.4.1  Additional national requirements for reporting of adverse e vents  66 
13 Monitor ing 68 
13.1  Direct Access to Source Data/Documents  68 
13.2  Source Documents and Source Data  69 
14 Data management  69 
15 Documentation and administration  70 
15.1  Investigator’s Brochure  70 
15.2  Deviations from Clinical Study Protocol  70 
15.3  Amendments t o the Clinical Study Protocol  71 
15.4  Final Repo rt 72 
16 Study Discontinuation 72 
16.1  Investigational Site Termination  72 
16.2  Prematu re discontinuation of the complete study  72 
16.3  Requirements for patient follow up  73 
17 Ethical considerations  73 
17.1  Independent ethics committee  73 
17.2  Ethical conduct of the study  73 
17.3  Patient  information and informed consent  74 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 17 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 17.4  Patient insurance 75 
18 Disclosure of data and publication policy  76 
19 Retention of records  76 
20 Study timeline  77 
21 Publication Plan  77 
22 References  78 
23 Appendix 79 
23.1  Appendi x I: Procedure for device read- outs 79 
23.2  Appendix II: Study Overview (German)  82 
23.3  Appendix III: Example of the phone call protocol  87 
 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 18 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 1 Study Overview  
Sponsor  Otto Bock Healthcare Products GmbH  
Short Study Title   Clinical trial comparing C -Brace  to KAFO/SCO  
Objectiv e To evaluate effectiveness and benefits in patient s with lower 
limb impairment in activities of daily living comparing the C -
Brace  microprocessor – controlled stance and swing orthosis to 
standard of care use of knee ankle foot orthosis/stance co ntrol 
orthoses  
Design Prospective inter national multicenter open- labeled randomized 
contr olled cross -over trial  
Devic es C-Brace , KAFOs , SCOs  
Primary Efficacy En d-
point  Improvement of static and dynamic balance by using C -Brace  
compared to KAFO /SCO  
Secondary Endpoints  1. To evaluate the effect of the C -Brace  compared to KAFO/SCO  
on gait, balance, plain level walking, walk ing during more 
challenging tasks and divided attent ion tasks during walk-
ing.  
2. To assess and compare the safe use of the C -Brace  comp ared 
to KAFO/SCO  in regards to falls: frequency of falls, severity 
of falls, fall -related injuries, fear of falling  and related 
treatment efforts.  
3. Evaluation of patient`s co nfidence in performing various 
ambulatory activities without falling using C -Brac e com-
pared to KAFO/SCO . 
4. Assessment of quality of life and re- integration to normal 
living using C -Brace  compared to KAFO/SC O. 
5. Assessment of disability and impact on productivity.  
6. Assessment of patient´s C -Brace  satisfaction and usage hab-
its compared to KAFO/SCO  
7. Reduced probability of falling more than once by using C -
Brace compared to KAFO / SCO  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 19 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Clinical Follow -up Screening,  2 baselines , vis it 1 after 3 months  usage of  device 1 
at home, visit 2 after 3 months usage of device 2 at home  
No of patien ts At least 56  randomized  
Inclusion criteria  • Patient has been tested with the Trial Tool (DTO) and 
demonstrated the potential to utilize the C -Brace  suc-
cessfully  
• Pati ent ha s a BBS score < 45  
• Lower limb functional impairment according to CE label 
wording  
• Prior active and compliant use of unilateral or bilateral 
KAFO or SCO in the past 3 months prior to enrollment in 
the study  
• Patient  meets minimum physical requirements to be fit-
ted with a C -Brace , such as muscle status, joint mobility, 
leg axis and proper  control of the orthosis must be guar-
anteed.  
• The User must fulfill the physical and mental require-
ments for perceiving optical/acous tic signals and/or me-
chanical vibrati ons 
• The existing muscle strength of the hip extensors and 
flexors must permit the contr olled swing -through of the 
limb (compensation using the hip is possible).  
• Patient´s commitment to use C -Brace  2 at least 1 -2  
hours per day 5 days per week - 
• Patient is ≥ 18 ye ars old  
• Patient is willing and able to independently provide in-
formed consent.  
• Person is willing to comply with study procedures  
Exclusion criteria  • Patient who is not able to follow the entire study visits or 
is unwilling/unable to follow the instr uctions  
• Patient was not able to use DTO  
• Patient who is not using an orthosis at least 1 to 2 hours/ 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 20 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 day for 5 days per week  
• Patient with body weight > 125 kg (includes body weight 
and heaviest object (weight) carried)  
• Patient with Orthoprosthesis  
• Patient with fl exion contracture in the knee and/or hip 
joint in excess of 10°  
• Patient with unco ntrolled moderate to severe spasticity 
(relative contraindication moderate spasticity)  
• Leg length discrepancy in excess of 15 cm  
• Pati ent with unstable neurological or cardi ovascu-
lar/pulmonary disease, cancer  
• Pregnancy  
• Patient using a C -Brace  
• Patient wit h known vertigo or with history of falls unre-
lated to orthosis use or unrelated to motor disability  
• Patient who has never been fitted an orthosis before  
• Patient is not abl e to answer the self -administered ques-
tionnaires independently; for patients with upp er ex-
tremity impairment is it allowed to verbally answer the 
questions.  
• Patient participating already in a study during this 
study´s dur ation  
• Patient participated in earli er C-Brace  studies  
Estimated Time Course  Estimated study duration:  
First Patient  In: 1 Mar 2019    
Last Patient  In: 31 Dec 2021  
Last Patient  Out:  31 Mar 202 3  
Principal Investigators  Site 1: Prof. Frank Braatz  
Site 2: D r. Axel Ruetz  
Site 3: Dr. Bea Hemmen 
Site 4: PD Dr. Rüdiger Rupp  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 21 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Site 5: Jason Weni ng, CPO, FA AOP   
Site 6: Tom DiBello, LO, CO, FAAOP  
Site 7: Chris Toelle, LCO, ACM   
Site 8: Eric Weber, LCPO, FAAOP 
Site 9: Dr. Alexander Krebs  
Clinical Site Locations  Site 1: Göttingen (D) 
Site 2: Koblenz (D)  
Site 3: Hoensbroek (NL)  
Site 4: Heidelberg (D)  
Site 5: Chicago, IL (USA)  
Site 6:  Houston, TX (USA)  
Site 7: Sarasota, FL (USA)  
Site 8: Seattle, WA (USA)  
Site 9: Wien ( AT) 
Clinical Project Mana ger  Dr. Marten Jakob  
 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 22 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 2 Abbreviation s 
AE Adverse Event  
ABC  Activities -specific balance confidence scale  
ADE  Adverse Device Effect  
BBS  Berg Ba lance Scale  
C-Brace  Axon Orthotic System  
CRF  Case Report Form  
CB2  C-Brace  2 (the New C -Brace ) 
CIP Clinical Investigation Plan = Pro tocol  
CPO  Certified Prosthetist/Orthotist  
DGI Dynamic Gait Index  
DTO  Trial tool  (Diagnostisc he Testorthese)  
EC Ethics  Committee  
GCP  Good Clinical Practice  
ICF Informed Consent Form  
KAFO  Knee Ankle Foot Orthoses  
PRO  Patient reported outcome  
OPUS  Orthotic and Pro sthetic User Survey  
QUEST  Quebec User Evaluation o f Satisfaction with Assistive Technology  
RNL  Re-integra tion to normal living  
SAE  Serious Adverse Event  
SADE  Serious Adverse Device Effect  
SAI Stair Assessment Index  
SCO  Stance Control Or thoses  
SF-36 Medical Outcome Study Short Form  
tbd To be defined  
WLQ  Work limitations questio nnaires  
US United States  
6MWT  6-Minute Walk Test  
 
 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 23 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 3 Background  
 
The estimated incidence for people with lower limb weakness due to neurologic, neu-
romuscular or orthop edic impairment, such as lower motor neuron injury, spinal cord 
injury, multiple scler osis, post -polio sy ndrome,  stroke, arthritis or trauma requiring  the 
use of a n orthosis for walking is about 394.400  cases in Germany  (1). It is  estimated 
that a pproximately 0 .01 % of those requiring an orthosis will benefit from a C -Brace . 
Distribution is  compar able in other cou ntries like the US.  
People with lower limb weakness due to neurologic, neuromuscular or orthopedic im-pairment, such as lo wer motor neuro n injury, spin al cord injury, mu ltiple sclerosis, 
post -polio syndrome, stroke, arthritis or tra uma may require the use of  a knee- ankle -
foot orthoses (KAFO) for walking. The conve ntional KAFO has a knee joint that can be 
“locked” in extension during ambulat ion, but this can cause abnormal gait patterns 
with hip hiking, circu mduct ion and vaulting duri ng walking (2). These gait  deviations 
using conventional KAFOs may contribute to chronic pain, decreased mobility and a higher physiologi cal energy cost  (2,3)   
Stance Control Orthoses (SCO) are usually knee ankle foot orthoses (KAFO) that have a 
built -in locking mechanism which locks the knee joint for the stance phase  and unlocks 
it for the swing phase of gait. The stance- control knee- ankle -foot orthosis (SCO) has 
addressed s ome of these issues by mechanically locking the o rthotic knee joint during 
the st ance phase of gait while a llowing free knee flexion during swing.  
 
These devices have been shown to improve gait kinematics and gait speed on level 
ground in comp ared to the u se of KAFOs  (2,4). Due to the method needed to en gage the 
knee lock for stance, however, users have reported increased mental effort to use these 
devices, specifically to di sengage the knee for initia tion of swing (5). Success in using 
SCOs ha s been limited by balancing the need to resist flexion in stance and providing a 
lightweight a nd small device. The chall enges that r emain for the SCO are to control the 
knee in flexion, missing knee  flexion under load and exte nsion phases and to switch 
smo othly be tween the phases (6).  
Current evidence finds that the benefit of KAFO use is for home mobility, general exer-
cise and standing (7) and that, in general, most patient s feel that the difficulties and 
inconvenience encountered with the orthoses and the modest increase in function do 
not warrant their acceptance for regular, daily use in functio nal acti vities  (7).  However, 
walking provides exercise to promote musculoskeletal and mental health benefits to 
counteract the effects of long- term wheelchair us e. It may als o increase functional in-
dependence, communi ty participation and re -integration ba ck to normal life and work . 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 24 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 On the other hand,  there is low knowledge about disability and the impact on work 
background as well as re -integration into work.  
A KA FO orthotic d evice that can provide mechanical support while allowing greater 
control in swing and stance phases of gait  may increase the u ser’s ability to walk with 
decreased metabolic cost and mental effort to allow increase functional m obility and 
parti cipation in d aily activities allowing a self -administered life.  
The C -Brace  orthotic system is  designed with custom thigh and calf shells connected by 
a monocentric knee joint with a microprocessor -controlled linear hydraulic damper. 
The orthotic knee is equipped with a sensor that detects the knee angle and knee angle 
velocity. The microprocessor controls extension and flexion dampening of the h ydrau-
lic knee joint separately by adjusting two valves with the help of servomotors and a planetary gea r set. In this way, the entire gait cycle is co ntrolled in real time. The C -
Brace  is a default -stance orthosis that switches into low flexion resistance for swing 
when a pre- set, customizable ankle m oment is exceeded, while the knee is simultane-
ously extended, follo wed by significant knee flexion. It switch es back to high flexion 
resistance for stance as early at the initiation of knee extension.  The C -Brace  offers con-
trolled stance knee flexion, knee flexion during weight -bearing and dynamic control of 
the swing phase. Knee flexion during weight bearing makes it possible to reciprocally 
descend ramps and stairs and to sit down with both legs loaded. We hypothesize that the use of C Brace  in comparison to conventional KAFO / SCO systems shall lead to a 
better balance associated with a reduced risk of falling, hence allo wing better participa-
tion and an increase in quality of life.  
 
C-Brace  Clinical data  
 
Title  Objective(s)  Compa rator(s)  Patient 
number  Published  
Prospective, pilot 
study to evaluate per-forma nce, p atient ben-
efits and a cceptance of 
a new gener ation of C -
Brace  micropr ocessor -
controlled stance and 
swing control o rtho-
sis– AOS Safety and func-
tional ity of CB2  KAFO/SCO  8 Study final 
Dec 2018  
Clinical Algorithm for 
Post -Stroke Gait Train-
ing with C -Brace functi onality  N/A 15 recruiting  
Micro -processor con-
trolled Knee -Ankle -Metabolic, func-
tional ity, safety  SCO  18 Study final, 
public ation 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 25 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Foot O rthosis (C -Brace ) 
vs. Stance -control 
Knee- Ankle -Foot Or-
thosis (SCO) and con-
ventional Knee- Ankl e-
Foot Orthosis (KAFO): 
Functional Ou tcomes 
in Individuals with 
Lower E xtremity I m-
pair ments  due to Neu-
rologic or Ne uromus-
cular Disease, Orth o-
pedic Disease or Trau-
ma (RIC)  in prepara-
tion  
A Pr ospective Registry 
of patients fitted with a 
micropr ocessor -
controlled knee ankle 
foot orth osis Functionality, 
safety  KAFO/SCO  150  recruiting  
Table 1: Published and non -published clinical data on C- Brace  
 
4 Ratio nale  
The C -Brace  microprocessor (MP) controll ed hydraulic system is the next generation in 
the development of lower limb orthos es allowi ng more control during the swing and 
stance phases of gait. The device will pr ovide better static and dynamic balance leading 
to a reduced risk of falling.  Improv ements may comprise stand to sit transfers, walking 
on uneven surfaces, slo pes and stairs. Su ch functions may help to improve patients´ 
mobility, integration, participation and quality of life.  
The study will spec ifically evaluate the potential of the C -Brace  to improve the efficacy 
in daily life activ ities and benefits for indiv iduals with lower extremity functional im-
pairments as compared to SCOs and co nventional KAFOs.  
 
5 Investigational Device Information  
Interv ention: C -Brace   
5.1 Manufacturer  
Otto Bo ck Healthcare Products GmbH  
Brehmstraße 16,  
1110 Vienna  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 26 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Austria  
 
Version invest igational device  
Model number : 17KO1=*  
Device name: 17KO1 C -Brace  Gelenkeinheit / C -Brace  joint unit  
Investigational d evice comp rises : 
- Microprocessor controlled knee joint (m odel no. 17KO1)  
- Custom made orthotic shells for each patient  
 
C-Brace  is a class I device according to 93/42/EEC Annex IX  and according to Regula-
tion (EU) 2017/745 Annex VIII  
CE-mark was obtained 14 Jun 2018.  
 For furth er technical details about the produ ct, product development and testing pro-
cedures  please refer to the Inv estigator’s brochure (IB ). 
5.2 Description of the i nvestigational device  
Intended use   
The C-Brace  microprocessor swing and stance control orthosis is u sed for patients with 
paresis or flaccid paralysis of the lower limbs (e.g. due to post -polio syndrome, t rau-
matic paresis including parapl egia) requiring orthotic knee support . 
 
Indications / Contraindications C -Brace  
Suitable patients will  fulfil the foll owing criteria : 
 
- Unilat eral or bilateral lower limb paresis or flaccid paralysis e.g. due to post -
polio syndrome, traumatic paresis inclu ding paraplegia.  
- Physical prerequisites such as muscle status, joint mobility and possible axis 
deviations are crucial and proper control of t he orthosis must be guaranteed.  
- The user  must fulfill the physical and mental requirements for perceiving o pti-
cal/a coustic signals and/or mechani cal vibrations  
- The existing muscle strength of the hip extensors and flexors must permit  the 
controlled  swing through of the limb (compensation using the hip is possible).  
 
Patients wil l not be suitable for using the system if  they show the following:  
Absolute contraindications:  
- Flexion contracture in the knee and/or hip joint in excess of 10 ° 
- Knee varus/val gus malposition in excess of 10°  
- Severe spasticity  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 27 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 - Body weight over 125 kg / 275 IBs  
Relative Contraindications  
- Moderate s pasticity  
 
Technical description of the C -Brace  
The C-Brac e consists of individually manufactured orthotic shells, whi ch interface with 
the thigh, shank and foot. The orthotic shells are made out of commonly used materials 
in orthotics.  
The knee joint is controlled by a microprocessor controlled joint unit, while  the ankle 
joint is designed according to the patient’s need s. Elastic elements ( such as the C -Brace  
carbon fiber spring) or state of the art orthotic joints can be used.  
 
Figure 1 C-Brace  existing of thigh, tibial and foot shell,  mpKnee joint and medial follower.  
 
Knee joint motion is controlled using  a microprocessor -controlled  joint (mpKnee joint) 
which consists of  microprocessor -controlled hy draulic cylinders that can pr ovide vari-
able resistance. The microprocessor uses the signals from various sensors to adjust the joint behavior in re al-time, accor ding to  situation (i.e. phase in gait cycle). For example, 
during stance phase of gait the knee joint provides high resistance to stabilize the pa-tient. During swing phase,  the knee joint switches to minimum resistance and is almost 
free (onl y inner friction of t he system). At maximum resistance,  joint motion is blocked. 
The joints are capable of providing any resistance between these extreme points. For further technical details abou t the mpKnee joint unit,  please refer to chapter 5.2. 1 
Technical description of mpKnee Joint . 
 
The patient has the possibility to turn the system on and off via a contro l panel. Fur-
ther more, the patient gets information on the control panel about the battery status, if 
service is requir ed (after a certain a mount of cycles or if a problem with the sensor is 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 28 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 detected by the system) and about the Bluetooth status  (see Figure 2: Control panel  of C-
Brace ). Bluetooth  can be initialized by the patient i f he/she wants to u se the Remote 
Control App. The App will be compar able to the one available for Ottobock’s micropro-
cessor controlled pro sthetic knee and foot prostheses G enium, C -Leg and Merid ium. 
The use and application of the control panel as well as t he Remote Control A pp is de-
scribed more detailed in the instruc tion for use.  
 
 
Figure 2: Control panel of C -Bra ce 
 
5.2.1  Technical description of mpKnee joint  
The knee joint  for the Brace s used in this  study as shown in  “Figure 3: Microprocessor 
controlled knee joint unit ” is controlled by m icroprocessor controlled hydraulics. The 
knee joint can only dissipate energy and is not capable of energy sto rage. As the hy-
draulic unit has two  valves, flexion and extensi on resistance can be controlled i nde-
pendently. This means that flexion resistance can be high but at the same time ex ten-
sion resistance ca n be low, which is a safety feature.  
The unit has a mo dular design with electronic components connected with the prop rie-
tary AXON bus, with the exception of the hydraulic sen sor. 
 
The system control is based on signals from several sensors:  
• 3D accelerometers and gyroscopes measure motion and orientation in s pace.  
• A hydraulic force sensor measures the load that is transm itted by the Brace  sys-
tem.  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 29 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 • Knee angle is measured with a special sensor based on magnetic principles.  
 
 
 
  
Figure 3: Microprocessor controlled knee joint unit  
 
The control paradigm is mainly based on the evaluation of motion signals. Thus,  it can 
provide optimum support in every phase of the gait cycle. In level walking,  the system 
would behave in the differ ent gait  phases according to the following table:  
 
Gait phase  Knee joint r esistance  Effect on gait.  
Heel strike High flexion  
Low extension  Stan ce phase stability, stance phase flexion 
is possible  
Mid stance 
(rollover)  High flexion  
Controlled extension Stance pha se stability  
Stance phase extension controlled for soft  
extension stop and improved propulsion  
Toe off  Low flexion  
Low extension  Swing initiation, knee can bend  
Extension is free.  
Swing phase flex-Controlled flexion  
Low extension  Knee flexion angle can be controlled to achieve a physiological knee angle  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 30 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 ion Extension is free.  
Swing 
phase ex-
tension High flexion  
Low exte nsion  Flexion resi stance is high to provide support 
in case of stumbling.  
Extension is free.  
Terminal 
swing  High flexion  
Controlled extension  Flexion resistance is high to provide support in case of stumbling.  
Extension is controlled for soft extension 
stop.  
Table 1: Des cription of the knee joint resistance depending on the gait phase and the respective effect on gait.  
The system only activates swing initiation at toe off if a signal pattern  that is typical for 
level walking is detected.  
The control sys tem is kept  as simple as possible;  it is principally based on posture co n-
trol. This method has proven to be a ppropriate  for the control of  prosthetic knee joints 
(e.g. C -Leg 4). For safety reas ons also load signals representing the knee moment are 
taken into account . Theref ore, t he knee joint does not switch to a low flexion resistance 
for swing initiation if a flexion moment is measured. Su ch “default stance” behavior of 
the sy stem is inherentl y safe.  
 
 
5.3 Necessary training and experience to use the investig ational  
device  (C-Brace ) 
5.3.1  Orthopedic  technician  
The orthopedic technician needs a C -Brace  (C-Brace 2) certification.  
5.3.2  Patient  
The patient  will be trained to put on C -Brace , to use the cockpit a pp and perform ad-
justments safe and routine ly. Training wil l be performed by a certified CPO or physio-
therapist.  
 
Patient  will be discharged with C -Brace  only if he/she demonstrated that he/she was 
able  to walk safely and is able t o program the device.  This will be a ssessed with a 
benchmark system within the ad aption  phase  (see section 7.3.4) . 
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 31 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 5.4 Comparator Devices  
The C -Brace  will be compared with the standard SCOs or KAFOs, which have been pre-
scribed in clinical routine to the patient. All CE registered SCOs or KAFOs are allowed.  
 
5.5 Accommodation to the devices  
During t he phase of system set up, patient s will receive appropriate accommodation 
support.  
For details of accommodation support, please see section  7.3.4.   
 
5.6 Specific medical or  surgical procedure i nvolved  
Not applicable . 
 
5.7 Receipt, distribution and usage  
During screening, the site will test the patients regarding the ability to use C -Brace . 
During this testing procedure, the parameters will be documented and sent to Ottobock  
afterwards .  
Final assembly of the patient -specific C-Brace  orthosis will be performe d eith er at Ot-
tobock SE  & Co. KGaA in Duderstadt, Germany  or at the study site.  In case, Ottobock is 
responsible for assembly, Ottobock will provi de the study site with the as sembled C-
Brace  orthoses. All orthoses will be labeled with a specific label “For  clini cal investiga-
tion only”. Shipment of the final assembled orthosis is done b y Ottobock Duderstadt. In 
case assembly is done at the study site, Ottobock Duderstadt will pr ovide the study site 
with sufficient mpKnee joints. The mpKnee joints will be lab eled “ For clinical investiga-
tion only”. Traceability of all investigational devices is ensured by maintaining a device 
accountability log.  
If stu dy patients decide not to keep C -Brace  for up to 24months after finishing the 
study, C -Brace  needs to be sent back t o Ottobock Duderstadt.  
6 Study objective s and hypotheses  
6.1 Objectives  
6.1.1  Primary objective  
Primary Efficacy Endpoint  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 32 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Improvement of static and dy namic balance by using C -Brac e compared to KAFO/SCO . 
 
6.1.2  Secondary objectives  
• To evaluate the effect of the C -Brace  com pared to KAFO/SCO  on gait, balance, 
plain level wal king, walking during more challenging tasks and divided a tten-
tion tasks during walking.  
• To assess and comp are the safe use of the C -Brace com pared to KAFO/SCO  in re-
gard  to falls: frequency of falls, severity of falls, fall -related injuries, fear of fall-
ing and  related treat ment efforts.  
• Evaluation of patient`s confidence in performing variou s ambulator y activities 
without falling using C -Brace  compared to KAFO/SCO . 
• Assessment of quality of life and re- integration to normal living using C -Brace  
compared to KAFO/SCO . 
• Assessme nt of disability and impact on productivity.  
• Assessment of patient´s C -Brace  satisfaction and usage habits compared to 
KAFO/SCO .  
• Reduced probability of falling more than once by using C -Brace compared to 
KAFO / SCO  
6.1.3  Endpoints  
Assessments will be taken at b aseline with the patient’s own orthotic device,  after 
completing the f irst random ization phase and after completing the second randomiza-
tion phase. Please refer to section 8  Outcome Mea sures . 
 
6.2 Hypothesis  
The primary hypothesis is that the microprocessor b ased C -Brace  technology will help 
mode rately active patients to improv e balance compared to a non -microprocessor con-
trolled KAFO/SCO.  
As a consequence, the C -Brace  should help reduce the risk of falling/falls in these pa-
tients and eventually make them more independent in their daily life activities i nclud-
ing their job and im prove their  quality of life, which represents the second ary hypothe-
sis of the is study.  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 33 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 7 Study design   
This is a pr ospective inter national multicenter randomized controlled cross -over open-
labeled trial.  
The study will have multiple  sites  in the United S tates, Germany, Netherlands and Aus-
tria. In total 5 6 patients will be recruited.  Patients can be enrolled in a competitive 
manner withou t any allocation .  
 
7.1 Experimental plan  
After obtaining informed consent , patients will be screened. Patients  fulfilling in clu-
sion/exclusion criteria will be enrolled in the st udy. After screening, a first baseline 
assessment will be conducted. Within maxim um 48 hours , a second set of baseline da-
ta will be collected. After wards the participants will be randomly assigned to be fitted 
either with C -Brace  or maintain  his/her KAFO/SCO . The ra ndomization procedure will 
be concealed  and assigned off -site. After fi tting , an accom modation  period follows that 
will last up to 14 days prior  home use. The first follow -up data collection  will occur af-
ter 3 months after the init ial home use period. Afterwards , the pa tients  will cross over 
to KAFO/SCO or C-Brace, respectively . The participants who were fitted with C -Brace  
will cross over to KAFO/SCO  and vice versa. A nother  accommodation  phase will be of-
fered for both C -Brace  and KAFO/SCO wearers  to ensure that the patient can properly 
use both devices  before t he cross -over h ome use period . The second follow -up data col-
lection will occur after 3 -months of home use. At the end of the study, t he patients can 
choose to keep C -Brace  until reimbursement or return to their original KAFO/SCO.  
7.2 Measures taken to minimiz e bias  
The res earch center will delegate the role of assessor to one trained employee. The as-
sessor will be responsible for evaluating f unctionality of partic ipants in the perfor-
mance- based tests in all phases of the study. During all performance tests, p atient s will 
be instructed to refrain from giving any comments. The certified prosthetist (CPO) and 
physical therapist cannot be blinded.   
7.3  Study visits  and procedures  
7.3.1  Patient  enrollment  
This study will enroll up to 150 eligible patients . At least 56  subjects passing screening 
will be r andomized.  Dropouts  shall be repla ced, a dropout  rate of 20 % is assumed . Re-
cruitment planning shall be done in accordance wi th the capabilities of the centers. 
Competitive r ecruitment shall be allowed.  All means to increase recruitment shall be 
taken.  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 34 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Treatment failures: C -Brace  mus t be fitted according to Ottobock instructions. During 
study visits, the C -Brac e fitting quality will be checked;  poor fitting quality needs to be  
corrected and may  be reported as adverse event (AE) or adverse device effect (AD E). For 
definitions, please r efer to section 12.2.      
Patients  who do not comply with using the  C-Brace  at least 1 -2 hours per day 5 days per 
week will be i ncluded in the intention to treat analysis only; however, they will be ex-
cluded fro m the per -protocol analysis.  
Potential patients will be called by the participa ting sites and pre- screened for s tudy 
eligibility. In addition, patients contacting the sites or visiting them on a routine basis  
can be also pre- screened.  
 
 
7.3.2  Screening  and basel ine procedures  
Pre-screening prior to informed consent may be done with chart r eviews or following 
standard of care assessments to determine if subjects may be potential candidates for 
the stu dy. Assessments performed exclusively to determine eligibility f or this study 
would be done only after i nformed consent has been obtained.  
Assessments performed for clinical routine and documented in patient´s records may 
be used for baseline even if they  have been done prior to informed consent b eing ob-
tained.  
A scre ening log will be tracked.  Screening failures will be documented.  
If the patie nt enrollment and screening is d one at a location separate from the orthotic 
clinic  (e.g. rehabilitation clinic ), remote screening including a video of the performance 
of the BB S will be done at the orthotic clinic to reduce patients ’ travel efforts to the  in-
vestigator . Patients must  give their informed consent before entering this remote 
screening procedure.  
Two bas eline assessments will be performed in order to generate a more confident 
baseline assessment. Both baseline assessments should be performed wi thin 1 or 2 
days.  Only the first  baseline measurement will be used for statistical analysis.  
7.3.2.1  The screening proce dures include : 
• Informed consent  
• Inclusion/Exclusion criteria  
• Ability of the patient to sufficiently use C -Brace  (via DTO testing)  
• Berg Balance Scale  
• Demographics: age, gender , ethnicity, weight, height, BMI  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 35 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 • General health information 
• Functional muscle tes t (Janda ) / Manual Muscle Testing (MMT)  
• Sensitivity test ( Rydel -Seiffer Test )  
• Passive range of motion assessment (neutral zero method)  
• Medical  history: Joint replacement, cur rent orthosis use, current use of assistive 
devices, fall history   
7.3.2.2  The first base line procedures include : 
• Review patient ’s eligibility criteria  
• Functional and self -reported baseline assessment (Full assessment  of outcome 
mea sures ) 
 
 
Performance Assessment  
Functional assessment will be done using the Berg Balance Scale, the 6 -minute wal k 
test, Dynamic Gait Index, and the Stair Assessment Index.  If the first baseline proce-
dure is performed within 24 hours of the screening, the results from the Berg Balance 
Scale testing, obtained during screening, may be used as first baseline value.  
Self – administered Questionnaires : 
Activity -specific Balance Confi dence Scale, Reintegration to Normal Living index ques-
tionnaire, EQ -5D-5L, SF36, Work  limitation  questionnaire and the OPUS questionnaire.  
For a detailed description of administe red questionnaires, please refer to section 8.2 . 
Note that screening and first baseline procedures  may be combined in one visit.  
For statistical analysis, only values from the fir st baseline will be used. Values from 
second b aseline will be used only to support  the values from the first b aseline.  
7.3.2.3  The second baseline procedures include : 
• Functional base line assessmen t (Performance assessment)  
7.3.2.4  C-Brace  potential  
Testing C -Brace  potent ial (DTO) with patients is done during screening to ensure the 
use is appropriate and possible. In the case,  a patient cannot  fulfill the test criteria;  this 
will be handled a s a screening failure.  
 
7.3.3  Randomization  
Patients are assigned to treatment groups by means of a state -of-the-art randomization 
procedure.  For details on the randomization procedure,  please ref er to section 10.3.1.   
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 36 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 7.3.4  Fitting  and  Accommodation  
7.3.4.1  KAFO  / SCO  
Patie nts entering the study wi ll use their existing fitted KAFO/SCO .  
Up to  10 hours of accommodation support with a physical therapist/orthotist will be 
provided in -house after enrollment  within 2 weeks. The progress of accommod ation 
will be assessed  and docum ented . Benchmarks will be used to check patients ’ ability to 
use their current orthosis . Two levels will be used for benchmarking:  
• Level 1, the mi nimum requirement for all pat ients to use their current device 
should be demons trated at two different po ints in time  (see 7.3.4.3) . 
• Level 2 will be documented for patients with higher functional status , walking 
outdoor s, over ground surfaces, steep ramps, slopes and clim bing stairs  with 
step -over -step pattern . 
 
7.3.4.2  C-Brace  
Up to  10 hour s of accommodati on support with a physical therapist/orthotist will be 
provided in -house after definitive fitting within 2 weeks. The progress of accommod a-
tion will be assessed  and documented . Benchmarks will be used to check patient’s  
readiness to be discharged with C -Brace.  
• Level 1, the minimum requirement for all patients to use C -Brace  should be 
demonstrated at two different point s in time  (see 7.3.4.3) . 
• Level 2 will be docum ented for pat ients with higher functional status , walking 
outdoor s, over groun d surfac es, steep ramps, slopes and climbing stairs  with 
step -over -step pattern . 
 
C Brace  accommodation support shall follow standardized Ottobock procedures.  
 
7.3.4.3  Benchmarks 
Level 1 b enchmarking requires independent donning/doffing of the orthosis, charging 
of the device  (if applicable) , transfers sit to stand / stand to sit, standing in the orth osis 
with or without assisted device for a minimum of 2 minutes, safe over ground ambula-
tion, ambulatory turns , to perform a swing phase , walking ramps with a low grad ient 
and climbing stairs with step -to pattern . CPO  or physical therapist  shall do benchmark 
assessment .   
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 37 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 C-Brace  and KAFO/SCO  home use may only be permitted after successful Leve l 1 
benchmark testing. C -Brace  settings shall be documented by pdf-exports  of the cockpit 
app and device read -out.  
Both devices shall be fitted with a step -count transponder . After 14 days, the patient 
will remove the step -count transponder from the ortho sis and will send it back to the 
study site  in a prepared envelope which will  be handed to the patient after passing the 
benchmark criteria (Level 1) . After having received the step -count transponder, the site 
investigator(s) and the sponsor will analyze  the daily step count of the patient.    
 
7.3.5  Home use (both arms ) / Follow -up phon e cal ls  
Patients will be followed up by phone calls  after discharge with KAFO/SCO or C -Brace : 
End of month 1,  end of month 2 . 
The purpose of these phone calls is to check if any n otable adverse events , device mal-
functions or falls have occurred. Pati ents should be remind ed during this call on use 
requirements and on the minimum use time of the device to avoid non-  or misuse. The 
phone call shall follow a detailed procedur e (see Annex III) , results will be documented 
in a CRF  and shall be co nducted by the i nvestigator.  
Patient is responsible to call the investigator in the case of malfunction, fall or other 
limiting event without any further delay . 
A patient  diary is to be  document ed by the patient to ensure proper collection of fall 
information and to brin g it at each visit.  
 
7.3.6  Study visit 1  
After 3 months of C -Brace  or KAFO/SCO home use , respectively , a full performance as-
sessment using clinical tests and questionnaires, a s defined  in 8.2 will be performed.  
During study visit 1, patients will perform t he fo llowing clinical tests and will fill out 
the following questionnaires:  
Clinical tests  
• Berg Balance Scale 
• Dynamic Gait Index (DGI)  
• Stair Assessment Index (SAI)  
• 6-minute wa lk test  
 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 38 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Questionnaires  
• Changes in curr ent assistive devices  
• Documentation of fal ls (Analysis of patient diary)  
• Documentation of fear of falling 
• Activity -specific balance confidence (ABC) Scale 
• EQ-5D-5L 
• Medical Outcomes Study Short Form (SF -36) 
• Orthotics &  Prosthet ics User Survey (OPUS)  
• Quebec User Evaluation of Satisfaction with Assis tive Technology (QUEST)  
• Reintegration to Normal Living (RNL) Index questionnaire 
• Work limitations questionnaires WLQ -25 
Device settings and step count shall be read out from C -Brace . An anamnestic interview 
is conducted to document possible changes in the medic al history, specifically the use 
of assistive devices  and to record AE´s, SAE`s and device malfunctions.  
Study visit 1 has to be planned 3 months after patients have pass ed the benchmarking 
criteria and have been discharged to use the orthosis. To facilita te the appointments 
with the patients, a time frame of - 1 to +2 weeks  around the scheduled visit is allowed.  
The following test sequence is recommended:  
Test sequence  
Documentat ion of falls  
Documentation of fear of falling  
Patient related outcome qu estio ns (only during study visit 2)  
Activity -specific balance confidence (ABC) Scale  
Berg Balance Scale (BBS)  
EQ-5D-5L 
Medical Outcomes Study Short Form (SF -36) 
Dynamic Gai t Index ( DGI)  
Stair Assessment Index (SAI)  
Orthotics & Prosthetics Us er Survey (OPUS)  
Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST)  
6-minute walk test  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 39 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Reintegration to Normal Living (RNL) Index questionnaire  
Work li mitations  questionnaires WLQ -25 
 
The clinical testing of the Berg Ba lance Scale and the Dynamic Gait Index  is to be doc-
umented additionally by video.  If possible, Stair Assessment Index and 6 -minute walk 
test is also to be documented by video.  Video files will be stored at the study site and 
transferred to the sponsor after completion of last -patient -last-visit milestone.  
7.3.7  Cross –over process  
Cross over of devices following procedure 7.3 .4 Fitting and accommodation shall be 
performed.  
7.3.8  Wash out phase  
In the arm “ C-Brace  cross -over to KAFO/SCO”,  a wash out phase of 4 weeks is  imple-
mented to take a poss ible carry over effect into account.  For safety reason s, wash out 
phase will begin after patient reaches  benchmark level 1.  
In the arm KAFO/SCO cros sover  to C-Brace , no carry over effect is estimated,  as it was 
not observed in pr evious studies.  
7.3.9  Study  visit 2 
After 3 months of C -Brace  or KAFO/SCO home use, full pe rformance assessment using 
clinical tests and questionnaires, as defined in 8.2 will be pe rformed.  
Procedures w ill follow the description in section 7.3.6 Study visit 1.  Two individual 
questions to evaluate patient -related outcomes (PRO) will also be asked.  
7.3.10  Patient ´s C-Brace  use after study end  
After the study documentation is completed, the in dividual study data c an be used to 
support a reimburs ement application according to local regul ations for the time after 
the study. If such an application is filed, the device may remain with the patient until 
reimbursement is granted but for a max imum of 24 months.  
Patients w ho finish the study on a KAFO/SCO but want to return on C -Brace will be re -
trained.  
Pati ents who  prefer to use their original orthosis shall also be re- accommodated.  
7.3.11  Transfer  of patients to C -Brace  registry for long term follow up  
In the United S tates and Germany,  a prospective  registry with a 3 -year observational 
period per patient is collecting data from clin ical routine fitting.  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 40 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Patients enrolled in a US or German study site  can be transferred after study end and 
after signing an informed consent for the registry. In this case, patients should return to 
their original orthosis for at least  2 weeks before entering the registry.   
7.3.12  Adaptations to the study procedure due to the COVID -19 pan-
demic  
Due to the outbreak of the COVID -19 p andemic, patients’ study visits were interrupted 
for the time of the lockdown.  This had significant impact on the s tudy procedure as 
well as on the patients’ individual study duration.  
The point of restarting patient assessments will be determined according to national , 
state a nd local regulations on COVID -19 contai nment. Starting dates may therefore be 
different per individual study site .  
In order to get comparable results before and after the lockdown, a full performance 
assessment using clinical tests and questionnaires, as defined in 8.2 will be performed . 
After  the performance assessment, patients will be re- asse ssed regarding the ability to 
reach benchmark Level 1 as described in section 7.3.4 .3. 
After successful Level 1 benchmark testing, patients will re- start the home- use phase in 
which they had been when the COVID -19 lockdown became effective. Home- use phase 
will b e performed as described in section 7.3.5.  
If patients were in the wash- out phase or before the start of a home -use phase, patients 
will start with the following home- use phas e according to protoco l after successful Lev-
el 1 benchmark testing.  
Patien ts wil l receive a StepWatch as noted in the footnote to the Study Schedule in sec-
tion 8.3.  
A device read -out will be performed as described in section 8.2.2.4.     
Patients will continue the study as out lined in 7.3.  
In case of further lockdowns or in cas e local regulations prohibit patients’ study visits, 
the study visits shall be re- organized and patients will continue with the study follow-
ing the procedure described above.  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 41 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Study Flow Chart   
 
 
 
Figu re 4: Study flow chart  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 42 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 8 Outc omes  measures  
8.1 General data collection  
Due to the nature of the study, several non- validated, self -designed questionnaires 
(SDQ) will be used as case report forms (CRF) to colle ct the neces sary data.  
 
General patient and orthosis use data will include such information as:  
• Patients ’ demography: patient age, gender, ethnicity, weight,  height, BMI   
• Patients ’ medical history: time since impairment, cause of limb impa irment, 
limb(s) impaired , surgical history,  comorbidities , medications, current o rthosis 
fitting , use of aids, falls, duration of orthosis support since impairment, etc . 
 
Data collection is completed by video documentation of the performance tests.  
 
8.2 Outcom e measures  
In terms of outcome measures, se veral questionnaires and performance- based 
measures w ill be used in the study.  
8.2.1  Primary study objective  
For the primary study objective,  the static and dynamic balance will be assessed using 
the Berg Bal ance Scale  (Version 2013) as primary efficacy endpoint . Measures  will 
be performed and compared at first baseline, after 3 months  with the current orthosis 
and after 3 m onths with C-Brace  by a physician, orthotist or physical therapist  when 
randomize d to the first treatment group , and at baseline,  after 3 mon ths with C-Brace  
and after completion of  4 weeks  was h out period and 3  months  with the  current ortho-
sis, whe n randomized to the second treatment group . 
The Berg Balance Scale is a 14 -item s cale designed to measure balance in adults in a 
clinical setting. W hen scoring, the lowest response category that appli es should be 
recorded. In each item, points should be deducted if the time or distance requirements 
are not met, the patient’s performance requires superv ision, or the patient requires 
assistance from sup port or examiner.  
The Ber g Balance Scale was investi gated in a variety of etiologies including patients 
suffering brain injury, sp inal injuries, Parkinson`s Disease, stroke, osteoarthritis and 
vestibular disorders. It was also investigated in older adults and within geriatric care. 
The tool is  recommended  in intervention research studies. The minimal detectable 
change in elderly  adults was determined to lie between 3.3 and 6.3. The BBS is as soci-
ated with cut off scores in elderly adults with a score of 45 a nd lower indica ting an in-
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 43 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 creased risk of falling ( 8) and a score below 40 being associated with almost 100% fall 
risk (9).   
 
This investigation includes subjects with a BBS score <  45 and hence investigating sub-
jects that are b elieved to be at an increased  fall risk.  
 Administration and burden: P erformance- based measure evaluated by physician, or-
thotist or phys ical therapist . 
  
 
8.2.2  Secondary study objectives  
8.2.2.1  Assessment of static and dynamic balance and functional m obility  
Assessment of static and dynamic bala nce and functional mobility is performed by us-
ing th e activities -specific balance confidence (ABC) scale, the d ynamic gait index  (DGI) , 
6-minute walk test, Stair Assessment Index  (SAI)  in patients using a C -Brace compared 
to KAFO/SCO . 
• Activity -specific bal ance confidence (ABC) Scale  
This test, along with a functional balance test, such as the Berg, will tell the clinician if 
their client is over - confident or under -confident about falling.  
The ABC is one of sev eral tools designed to measure an individual’s  confidence in 
his/her ability to perform daily acti vities. These tools were d esigned for use with older 
adults. The ABC was desi gned to include a wider continuum of activity difficulty and 
more detailed item d escriptors than the Falls Eff icacy Scale (FES ). Fear of falling is im-
portant to assess because it is a likely confounder in measuring po stural performance. 
Deterior ation in  balance may result from activity restriction mediated by the fear of fall-
ing. 
Administration and Burden:  Patient self -administer ed; 5 -10 min  
 
• Dynamic gait index (DGI)  
The Dynamic Ga it Assessment is an 8 -item  test used to assess balance during walking 
task s. It has a max imum score of 24  with each item being scored 0 -3. It may be per-
formed with or without an assistive device; however , individuals lose a point on all 
items requiring a d evice.  
Administration and burden: P erformance- based measure evaluated by p hysician , or-
thotist or physical therapist . 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 44 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 • 6-minute walk test  
The 6 -minute walk t est is performed as an objective evaluation of f unctional exercise 
capacity. The 6 -minute walk test i s easy to administer, well tolera ted, and typically re-
flective of activiti es of daily living. The test measures the distance that the patient can 
walk on a flat, hard surface, indoors, in a period of 6 m inutes. The walk test is p atient 
self-paced and asses ses the level of functional capacity. Patients are allowed to stop 
and res t during the test, ho wever, the timer does not stop. If the p atient is unable to 
complete the time, the time stopped is noted and  reason for stopping prematurely is 
recorded.  
Adminis tration and burden: P erformance- based measure evaluated by physician, or-
thotist or physical therapist . 
• Stair Assessment Index ( SAI) 
The Stair Assessment In dex ( 10) is a 1 4-point ordinal scale (from 0 to 13) used to as-
sess different gait patterns during ascent or descent of stairs. It was developed to de-
tect differences in functi on with different knee units for transfemoral pro sthetics.  Stair 
ascent and stair  descent pattern will be assessed separately.  
8.2.2.2  Measurement of safety and falls  
Patients will keep a pa tient  diary in each home use period .  
To measure the safe use of C -Brace  compared to KAFO/SCO , documentation will be 
done in the diar y and information will be transferred to the CRF  during study visits a nd 
phone calls . 
• Falls  
Principal investig ator or his d elegates interview  patients every month for occurrence of 
falls,  respectively occurrence of AEs/SAEs  on the phone respec tively ask fo r falls in 
study visits.  
In the case falling occurs, the following inf ormation is obtained from the patient and 
documented in the CRF  per fall :  
Mild fall:  no injury, bruising , abrasions, hematoma without physician / out -patient 
consultation  
Moderate fall:  bruising, sprains, cuts, abrasions, or a reduction in physical functi on 
for at least three days, or if the participant sou ght out -patient medical help (1 1) 
Serious fall:  fracture or admission to hospital or if any wounds needed stitches (su-
tures) (11) 
Wha t was the consequence of the fall:  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 45 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Diagnosis, office -based physician, ambulance visit, radiology, therapy, length of hospi-
tal stay, follow up visits . 
Frequency of falls are d ocumented as well.  
• Patient reported outcomes questions regarding to fear of falli ng 
One question will address patients ’ fear to experience a fall indoor  and a second  one to 
fall outdoor. The rating will be  done on a n 11-item  scale (0 = no fear  to 10 = max . fear) . 
In addition to each question,  patient s will be asked to explain in their  own words the 
scenario of falling.  
Administration and Burden:  Patient self-administered; 1 min . 
If an AE/SAE occurs,  it will be processed as described in section 12.3.  
 
• Proba bility of falling more than on ce when using C -Brace compared to 
KAFO / SCO  
 The p robability to fall more than once using C -Brace will be calculated and compared 
to the probability to fall more than once us ing KAFO / SCO. For details of the statistical 
anal ysis, see section 10.3.    
 
8.2.2.3  Quality of Life and Re -integration to normal living  
Measurement of quality of life and re- integr ation to normal living using C -Brace  com-
pared to KAFO /SCO  will be done u sing RNL index, EQ -5D-5L, WLQ -25, OPU S, SF -36, 
QUEST, and PROs.  
• Reintegration to Normal Living (RNL) Index questi onnaire . 
The reintegration to normal living will be measured using the Reintegration to Normal 
Living (RNL) Index questionna ire. 
A measure of community reintegration, which co vers areas such as participation in rec-
reational and social activities, mov ement within the community and the degree of com-
fort the individual has in hi s/her role in the family and with other relatio nships . 
11 items measuring satisfaction regarding perceiv ed physical functioning, and social 
and emotional life.  
Internal consistency from  a sample of persons with acute mobility impairments (includ-
ing persons  with sp inal cord injury), yielded a Cronbach α = .91 . The RNL Index has 
been found to have good constru ct validity  (12) . 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 46 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 Scoring: There are different scoring algorithms for this measure.  There is a 1) visual 
analog scale ranging from 0 to 10; 2) a three- point scor ing sy stem; and 3) a four -point 
scoring system. Regardless of the scoring system used, higher scores repr esent higher 
levels of participation.  
Administration and Burden:  Patient self -administered; 30 min . 
The RNL was developed by Wood -Dauphinee, Opzoomer, Williams, Marchand, and 
Spitzer in 1988 (12) . 
The RNL  has been tested for use with individuals with stroke, malignant tumors, de-
generative heart di sease, central nervous system disorders, a rthritis, fractures and am-
putations; spinal cord injury; traumatic brain injury; rheumatoid arthritis; subarach-
noid hemorrhage; hip fracture; physical dis ability; and community -dwelling elderly  
(13) . 
• EQ-5D-5L 
The EQ -5D-5L is a standardized  measure of heal th status developed by the EuroQ ol 
group, applicable to a wide range of health conditions and treatments and has wid e-
spread currency outside the profession. It is often referred to as a quality of life ques-tionnaire.  
The EQ -5D-5L, is a very simple measure, which patients complete at the start and end 
of treatment. Its name means 'EuroQol –  5 Dimensions – 5 Le vels' and comprises five 
dimensions of health: mobility, ability to self -care, ability to undertake usual activities, 
pain and discomfort, and anxiety and depression. There are five options (lev els) under 
each domain.  
Administration and Burden:  Patient self -administered; 10 min . 
• Work limitations questionnaires WLQ -25 
The Work Limitations Questionnaire (WLQ -25) was developed by Lerner and colleagues 
(14). It is one of the most commonly used questionnaires to evaluate at -work disability 
and productivity loss. It contains 25 items arranged under four subscales addressing 
four dimensions of job demands namely: time demands, physical demands, men-
tal/interpersonal demands, and output demands. The time demands subscale contains five items on punctuality, pacing, and productivity. The physical demands subscale has six items covering static positioning, moving around, lifting, repetitive movements, posture, and use of tools. The mental or interpersonal demands subscale contains nine 
items that assess concentration and on -the- job social interactions. The output demands 
subscale contains five items determining the volume and quality of work ( 14). 
• Orthotics & Prosthetics User Survey (OPUS)  
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 47 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 The Orthotic and P rosthetics User Survey (15) is a self -report questionnaire, which is 
designed to evaluate the outcome of orthotic and prosthetic services. Three of the five 
domains  will be administer ed: lower limb fun ctional measure, health- related quality of 
life and satisfaction with device. The d omains of upper limb fun ctional measure and 
satisfaction with service are not appl icable in this study.  
Administration and Burden:  Patient self -administered; 15 min . 
• Medical Outcomes Study Short Form (SF -36) 
The SF -36 is a 36- item scale constructed to surv ey health status and quality of life. The 
SF-36 assesses eight health concepts: limitations in physical activities because of 
health problems; limitations in social acti vities because of physical or emotional prob-
lems; limitations in usual role activities because of physical health problems); bodily 
pain; general mental health (psychological distress and well -being); limitations in usu-
al role activities because of emotional problems; vitality (energy and fatigue); and gen-eral health percep tions. The standar d form of the instruments asks patients  to reply to 
questions accor ding to how they have felt over the previous week. The items use Likert -
type scales, some with 5 or 6 points and others with 2 or 3 points. Sample items include “How much bodily pain have y ou had d uring the past 4 weeks”, and “How much of the 
time during the past 4 weeks have you felt so down in the dumps nothing could cheer you up? ” The SF -36 has been widely used and has excellent psychometrics.  
More information on Version 2 can be found on the SF -36 website: http://www.sf -
36.org/tools/sf36html  
Administration and Burden:  Patient self -administered; 10 min . 
 
•  Quebec User Evaluation o n Satisfaction with Assistive Technology (QUEST)  
The QUEST 2.0 evaluates a patient's satisfaction with various assistive technologies. The 12-item  instr ument is used to assess satisfaction with a specific assistive device; 
eight of these items assess characteri stics of that assistive device in terms of the follow-
ing dimensions: dimensions (size), weight, adjustments ; safety, durability, simplicity 
of use, comfort, and effectiveness .  
The remaining four items assess service and include service delivery, repairs and ser-
vice of the device, professionalism of service, follow -up se rvice.  
Patients are asked to rate their s atisfaction for the device on a five -point  scale that 
ranges from "not sati sfied" at all to "very satisfied".  
Finally, patients are asked to choose the three most important items related to the as-sistive device in ques tion.  
Administration and Burden:  Patie nt self -administered; 10 min . 
 CLINICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 48 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29  
•  Patient -Related Outcome  Questions  
Patient s will be asked how the specific orthoses affected  activities they  enjoy and their  
quality of life (5 levels each, 2 questions ). In addition to that , patients are asked to pro-
vide in a free text field information on these two topics . 
Administration and Burden:  Patient self -administered; 4 min . 
 
8.2.2.4 Device Read Outs  
• Setup  App:  
A pdf-export  and storage of the data file will be done at definitive fitting , every time a 
change in th e settings i s done and at the follow up visits.  
• Step Count  
A step count  transponder will be fixed on C -Brace  and on KAFO/SCO  before starting the 
home use phase.  It will be read out after each observational period  (14 days) .  
For details on the procedures, please refer  to section 23.1 (Appendix I).  
8.2.2.5  General statement to self -administered patient questionnaires  
The patient fills in the questionnaires after instruction of the invest igator. If a patient 
has an upper extremity i mpairment which does not allow him/her to fill in the ques-
tions, it is allowed that he/she answers orally  and data entry will be performed by the 
investigator, the CPO or PT .  The patient  is placed in a sep arate room. After filing out 
the investigator check s the questionnaires for completeness only. Questio nnaires are 
available in English and German. If translation into another language is necessary,  this 
will be done by a n official translat or. 
 
 
 CLINICAL  
INVESTIGATION PLAN  Document number:  PD-PS00120016A -001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace to KAFO/SCO  Project no.  PS00120016A  
 
Otto Bock  Confidential  Page 50 of 89 
Qualitätsmanagement  Otto Bock Healthcare Products  GmbH 
Bez. FO -704 Version: V1A zu SOP K -1-29 8.3 Study schedul e 
Visit 
IC 
Inclusion/ 
Exclusion  
Medical  
Histor y 
BBS 
DGI 
SAI 
6MWT  
Step count  
ABC  
2PRO  
WLQ  
RNL 
EQ-5D 
SF-36 
OPUS  
QUEST  
C-Brace Se t-
tings  
Fall history / 
Fear of falling  
Patient Diary  
AE/SAE/DD  
Screening  x x x x                x 
1st bas eline    x x x x  x  x x x x x x  x  x 
2nd baseline    x x x x             x 
C-Brace Fitting1                 x   x 
Training/  
benchmarks(1)         x2           x x 
Phone call (1)                    x x 
Phone call (2)                    x x 
Additional Study visit  (COVID -19)   x x x x x  x  x x x x x x x3 x x x 
Additiona l Training/ benchmarks  
(COVID -19)         x2            x 
Study visit (1)    x x x x x  x  x x x x x x x3 x x x 
Training/  
benchmarks (2)         x2            x 
Phone call (3)                    x x 
Phone ca ll (4)                   x x 
Additional Study visit (COVID -19)4   x x x x x  x  x x x x x x x3 x x x 
Additional Training/ benchmarks  
(COVID -19)4        x2            x 
Study visit (2)    x x x x x  x x x x x x x x x3 x x x 
 
1Order shown for subject s randomized to start with C -Brace  for whom  casting is done after screening. C -Brace fitting to be done after Study Visit (1) for subjects starting with  existing orthoses . 
2StepWatch affixed to either existing orthosis or C -Brace after benchmarks during tr aining are achieved.  
3For subjects randomized to C-Brace only.  
4For subjects restarting after cross -over  
 CLINICAL  
INVESTIGATION PLAN  Docum ent 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C -Brace  to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 51 of 89 
Qualitätsmanagement  Otto Bock Healthcare P roducts  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 9 Patient population  
9.1 Number of patients to enroll   
Up to 150 patients  fulfilling the inclusion and exclusion criteria will be enrolled in the study.  At least 
56 subjects passing screening will  be random ized . All sites are allowed to recruit  patients competi-
tively a ccording to their possibilities. Patient screening and enrol lment will be performed in close 
collaboration with  the sponsor to avoid over -recruitment . 
Potential patient s will be called by the p articipating centers and may be pre -screened for study eligi-
bility. In addition,  patient s contact ing the centers or visiting them on a routine basis  can be also pre-
screened.  
Once a potential participant using a unilateral KAFO or SCO has been identi fied, study clinician may 
contact the potential patient  or study sta ff will contact the poten tial patient  on behalf of the principal 
investigator , starting with a letter followed by a phone call to the potential patient . 
A screening log will be tracked.  
9.2 Durati on individual patient’s participation  
Each patient should be obs erved 8-9 months depending on which orthos is is used before the crosso-
ver.  
9.3 Inclusion  and Exclusion Criteria:  
Patient s must meet all of the inclusion and must not meet any of the exclusio n cr iteria to be regis-
tered to the study.  
Study treatment may not begin until a patient  is regi stered.  
9.3.1  Inclusion criteria  
- Patient has been tested with the Trial Tool (DTO) and demonstrated the potential to u tilize 
the C -Brace  successfully (see section benchmar ks: independent donning/doffing of the or-
thosis, charging of the device, trans fers sit to stand/stand to sit, standing in the orthosis 
with or without assisted device for a minimum of 2 minutes, safe over ground ambulation, 
ambulatory turns and to perf orm a swing phase).  
- Patient has a BBS score <  45 
- Lower limb functiona l impairment according to CE label wording  
- Prior active and compliant use of unilateral or bilateral KAFO or SCO in the past 3 months 
prior to enrollment in the study  
- Patient meets minim um p hysi cal requirements to be fitted with a C -Brace , such as muscle 
status, joint mobility, leg axis and proper control of the orthosis must be guaranteed.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 52 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 - The User must fulfill the physical and mental requirements for perceiving optical/acoustic 
signals and/ or m echanical vibrations  
- The existing muscle strength of the hip extensors and flexors must permit the controlled 
swing -through of the limb (compensation using the hip is possible).  
- Patient´s commitment to use C -Brace  2 at least 1 -2 hours  per day 5 da ys p er we ek- 
- Patient is ≥ 18 years old  
- Patient is willing and able to independently provide informed consent.  
- Person is willing to comply with study procedures  
9.3.2  Exclus ion criteria  
- Patient who is not able to follow the entire study visits or is unwilling/unable to fo llow the 
instru ctions  
- Patient was not able to use DTO  
- Patient who is not using an orthosis at least 1 to 2 hour s/ day for 5 days per week  
- Patient with body weight > 125 kg (includes body weight and heaviest object (weight) car-ried)  
- Patient with Orthoprosthesis  
- Patient w ith flexion contracture in the knee and/or hip joint in excess of 10°  
- Patient with uncontrolled moderate to severe spasticity (relative contraindication moder-
ate spasticity)  
- Leg length discrepancy in excess of 15 com  
- Patient with unstable neu rological or c ardiovascular/pulmonary disease, cancer  
- Pregnancy  
- Patient using a C -Brace  
- Patient with known vertigo or with history of falls unrelated to orthosis use or unrelated to 
motor disability  
- Patient who has never been fitted an orthosis before 
- Pati ent is not abl e to answer the self -administered questionnaires independently; for pa-
tients with upper e xtremity impairment is it allowed to verbally answer the questions.  
- Patient participating already in a clinical study during this study´s duration  
- Patien t participated  in earlier C -Brace  studies  
 
Additional determination of exclusion criteria for Austrian centers:  
Pregnant and nursing women are NOT allowed to participate in this study.  
Women of childbearing age are only allowed to participate in this stud y, if they have confirmed that 
they are not pregnant before the study (according to a pregnancy test). They will be asked to perform 
pregnancy tests once a month during the study. Female patients will be asked to inform the investi-
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 53 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 gator immediately, if they become pregnant during the study, or suspect that they are pregnant. 
Their participation in the study will be  terminated under these circumstances.  
9.3.3  Drop out or early termination of the study  
Patient s can withdraw from the study at any time and for any r eason. This de cision has no impact on 
the patient’s medical care. In case of early termination, the invest igator must document the reasons 
as co mpletely as possible. The investigator can temporarily or permanently discontinue the patient 's 
study partic ipation for any re asons that are in the patient 's best interest, particularly in cases of seri-
ous adverse events. If a patient  is lost to follow -up, the invest igator will use all available means to get 
into contact with him or her. After three weekly telephone reminders, th e patient  will be recor ded as 
lost to follow -up. 
The investigator will fill in the reason for the drop out or early termination of follow -up in the case 
report form.  Patient who drop out of the study may not keep the C -Brace up to 24 months a s de-
scribed in  section 7.3.10.  
 Dropouts  will be replaced  until the milestone last patient in was reached . 
10 Statisti cs 
 
The goal of this study is to assess the improvement of static and dynamic balance by using C -Brace 
compared to KAFO/SCO which should in consequence hel p reduce the risk of falling/falls in these 
patients.  
10.1 Sample size calculation  
 The sample size calculation is based on the hypothesis as described in 6.2 and crossover study de-
sign as described in 7. The number of recruited patients however w ill be larger than what would be 
needed to fulfill the requirements of the primary efficacy endpoint in order to achieve a higher power for any tests performed on secondary objectives and to improve the likelihood that the random allo-
cation of patients res ults in simila r baseline characteristics in the compared group.  
Sample size calculation was performed with G*Power 3.1.9.7 or manually as described.  
 
 
 
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 54 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 10.1.1  Primary efficacy endpoint  
 
The efficacy of the microprocessor based C -Brace  technology compared to  a non -micropr ocessor con-
trolled KAFO/SCO will be determined through the detection of a statistically significant improvement 
of the Berg Balance Scale.  
One null -hypothesis will be tested in the confirmatory analysis:  
  
 
Sample si ze calculations are based on a mean group difference 
  = 6.6429 between the C -Brace tech-
nology compared to a non -microprocessor controlled KAFO/SCO and a standard deviation 
  = 
4.9085 of this difference.  
The estimations of the param eters come from paired observations in the RIC study combined with the 
paired observations of 4 patients from the Wien/Goettingen study (RIC combination study). In total, 14 patients in the RIC  combination study were considered to determine the estimates. All the includ-
ed patients displayed a Berg Balance Scale of less than 45.  
To test the hypothesis of an expected effect in one direction a one- tailed paired  t-test will be used.  
At an 
 level of 0.0 5 and a power of 0.8, a total of 6.4557 of pati ents  are needed as calculated from 
the t -distribution. Under the assumption of a dropout rate of 20% a total of 9 patients  would need to 
be recruited.  
 
10.1.2  Secondary  endpoint s 
An improvement in patients balance is hypothesized  to aid the patients in their dail y life and poten-
tially influence some of the other outcome measures collected in this study. These measures will be 
explored without a strict expectation for the magnitude of expected change. Due to the expected na-
ture of the distribution of the number of fal ls or rather the proportion of patients to fall more than 
once with the device C -Brace, these measurements would require the largest sample size in ord er to 
detect significant improvements at a reasonable power level.  
If the probability to fall more than o nce with the device C -Brace  is significantly lower than the proba-
bility to fall more than once with the device KAFO /SCO it could be used as a supporting argument to 
relevance of a potentially identified improvement in the primary efficacy endpoi nt. Prev ious observa-
tions on the RIC combination data however revealed a low expectancy of the probabilities to fall more than once with either KAFO /SCO and C -Brace device during the observed time span. A proba-
bility to fall more than once of 
 with th e device C -Brace and a  probability to fall more 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 55 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 than once of 
  for the device KAFO/SCO was  recorded  for 
  paired observations  in the RIC 
combination study.  
The sample size needed to  detect a difference of 
  for the pair ed pro-
portions with on the basis of one- sided McNemar’s Z -test without continuity correction is calculated 
as 
 
where 
  
At a significance level of 0.05 and a power of 0.8, a total of 44.2386 of patients would be needed. 
Under the assumption of a  dropout rate of 20% a total of 56 patients would need to be recruited. We 
recognize that the inclusion of a continuity correction may be more appropriate given the small pro-
portion to fall more than once with either type of device and that a shift in the  expected proportions 
away from zero would drastically inc rease the number of patients needed to detect the difference to 
show a significant difference. Regardless the merit of the observing these proportio ns at a higher ab-
solute occurrence will yield a so und basis for future studies. For this reason,  the number of patients 
to be included in the study is based on this value.  
 
10.2 Management of missing, unused or spurious data  
 
If data are missing, illegible or i ncoherent, requests for further information will be  sent to the inves-
tigator in question. Although every eff ort will be made to ensure that each patient’s data is complete, 
some patients may not have data on one or more measures.  
For the intention- to trea t analysis the missing data will be imputed. The imp utation method will de-
pend on whether the missing data a re at baseline or follow -up visit as well as the reason for the miss-
ing data as further described below.  
Missing baseline data for patients will be imputed . For missing data  in any of the measurements  
which are taken again at the second baseline, these values might be used in place of the first base-
line measurement. Evaluation whether other missing baseline data might not be missing at random, 
will be done by exploring patterns of missing  data within d ifferent measurements and patients for 
which data was collected.  
Strong evi dence for missing data patterns within measurements of secondary interest may lead to the 
exclusion of such measurements for any supportive analysis  and will be documented in the st udy 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 56 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 report accordingly. In case such a pattern is observed within the measu rement of primary interest 
may lead to the study being declared invalid in regard to  the analysis planned for it.  
Appropriate data management as def ined in the protocol should reduce the chance of this being the 
case. Strong evidence for missing data patterns within patients of specific characteristics will be 
evaluated and might be indicative of a serious limitation to the study and could potentially  lead to 
the study being declared  invalid. Previous studies on the topic have not shown this to be very likely 
in the patients that fulfill the inclusion criteria of the study. Where data is assumed to be missing at 
random multiple imputation and a sensiti vity analyses  will be used . 
In or der to perform a sensitivity analysis, patients who term inated treatment early, will be imputed 
using multiple imputation methods in order to substitute missing values. Here, multiple copies of the origin al dataset will be generated by replacing missing va lues using e.g.  a multivariate normal dis-
tribution. Each  of these complete sets will  be analyzed  as complete sets and the corresponding pa-
rameter and standard error estimates will be combined with taking the uncertainty of the imputation 
process into accou nt. 
For the patients missing follow -up data, proportions  of missingness, type of missing measurements, 
patient characteristics and baseline value levels will be explored in order to detect patterns of mis s-
ing data. If data is assumed to be missing at random the following imputation strategy will be used.  
 
A lin ear mixed effects model with the outcome measure as dependent variable will be fitted to the 
data. This model will use the treatment group and perio d as fixed factor and the first baseline meas-
ure as co variate. Random patient effects will be introduced for  the intercepts and thus taking the cor-
relation within patients into account. The analysis implicitly uses a weighted average to estimate the 
outcom e measures, with estimations  coming from the complet e observations and from the observa-
tions with missing va lues.  
Missing data for study patients at follow -up on C -Brace, KAFO/SCO or both  because they 1) died, 2) 
are lost to follow -up (LTFU), 3) withdrew f rom the study or were withdrawn from the study by the 
investigator, 4) miss the follow -up visit or 5) do not  complete the outcome measure at follow -up, will 
be imputed by using a mixed model with a random intercept for patient and treatment group as pre-
dictor variables. 
The details of the imputations method s applied will be documented in the study report.  
 
10.3 Planned statistical analysis  
In general, the most suitable statistical analysis consistent with the form of data will be u sed and the 
underlying assumptions of the statistical method will be verified throu gh appropriate pre -tests.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 57 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 The analysis will be performed on the intention- to-treat (ITT) population and then on the per -
protocol (PP) population. The ITT population is defin ed as all the patients randomized into their ran-
domization group, regardless of the treatment received or their outcome in the study. The PP popula-
tion is defined as all the patients in the ITT population without any major protocol deviations  
For the outcomes measures being evaluated, three assessments are undertaken:  
after base line me asurements with original orthosis (first baseline measurement)  
after first follow up measurement with the C -Brace or original orthosis  
after second follow -up measurement with the C -Brace or original orthosis  
Quantitative variables will be summarized us ing standard descriptive statistics (average, standard 
deviation, median, minimum and maximum, first and third quartile). Qualitative variables will  be 
described using group sizes and frequencies. When relevant, 95%confidence intervals will be given.  
Pati ent characteristics at enrolment will be presented and compared in each group to ensure the 
groups are initially comparable. The features of any pat ients lost to follow -up will be studied  and 
influence the imputation strategy as described in 10.2 . 
Patient pro file plots for the outcome measures in both treatment groups for all three assessments will 
be viewed, showing imputed values. Furthermore,  the group means in each treatment group will be 
evaluated. Outcome measures will be visualized for the crossover per iods in scatter  plots of first fol-
low up measurement against  second follow -up measurement in both treatment groups i.e. period vs 
period plots.  
 
10.3.1  General patient and orthosis use data  
Assessments will be disp layed in summary tables.  
 
10.3.2  Primary efficacy outcom e 
One null -hypothesis as outlined in section 10.1 will be tested in the confirmatory analysis.  
Abso lute values and changes from first baseline and follow ups respectively  will be presented for the 
Berg Balan ce Scale after 3 months of treatment using descri ptive summary statistics for each treat-
ment period. Moreover,  percentage changes from baseline and follow ups respectively  will be dis-
played.  
The confirmatory inferential statistical evaluation of the primar y outcome measure will be based on a 
linear mixed  effects model with the Berg Balance Scale as dependent variable. This model will use 
the treatment  group and period as fixed factor and the first baseline Berg Balance Scale as covariate. 
Random patient eff ects will be introduced for the intercepts and thus t aking the correlation within 
patients into account.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 58 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 The confirmatory analysis of the primary ef ficacy endpoint will be done for the intention- to-treat 
population. Additional efficacy analyses will be con ducted for the per -protocol population. The p -
values of these analyses will be interpreted in the exploratory sense only.  
 
10.3.1  Secondary outcome analysi s 
Analyses for the secondary outcome measures will be performed for the intention- to-treat population 
as well as for the per -protocol population. All inferen tial analyses for the secondary efficacy varia-
bles will be interpreted in the exploratory sense. Al l secondary outcome measures will be evaluated 
by using descriptive statistics primarily, absolute values at  each time point and if appropriate chang-
es from firs t baseline and follow ups respectively . These analyses will be performed in a similar way 
as th e primary efficacy outcome using a linear mixed effects model when appropriate.  
Additional attention will be  paid  to the exploration of the measurements of s afety and falls. The 
number of Falls is expected to be reduced in general by using a C -Brace, but t he extent  of a possible 
reduction remains uncertain. Therefore,  frequency of falls, severity of falls, fall -related injuries, fear 
of falling and related treatment efforts will be explored in rigorously  in order to formulate appropri-
ate hypothesis for futu re research.  
In the past the reduced probability of falling more than once by using C -Brace compared to KAFO  / 
SCO showed the most promise as a reliable meas ure t o compare the two device types, since it was 
less sensitive to outliers e.g.  patients with a h igh number of falls on either device as compared to the 
total number of falls. However,  sample sizes in prio r research were relatively small and estimations 
for po tential differences remain uncertain, albeit of great clinical interest.  
Therefore,  we explor e whether  a reduction in the probability of falling more than once using the C -
Brace can be detected by a Mc Nemar Test for paired proportions. This test will  likely  be underpow-
ered in comparison  to the expected best -case scenario used in the sample size ca lculation and will be 
reported accordingly.  
 
10.3.2  Randomization procedure  
Randomization will be performed by site  in random permutated blocks of 6 by allocation order. A  
randomization sequence will be produced and integra ted into the electronic case report form  to de-
fine the randomized treatment order ( X or Y device) and provide the investigator with this infor-
mation  during the enrolment vi sit. 
 
10.4 Interim analysis  
An interim an alysis will be performed after at least 35  patients have completed the study . After the 
interim analysis, it will be decided whether: 1) the sample size must be increased 2 ) the study will be 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 59 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 stopped early for fu tility , or 3) interim hypot hesis testing will be don e for the primary o bjective and 
select second ary objectives . 
 
The interim analysis will be performed for the primary endpoint  (BBS) . A statistical  power calcula-
tion  will be performed  based on the  observed  intraindividual changes  (IIC) between  C-Brace and 
KAFO arms . The following rules will be applied:  
1. If the power based on ob serve d mean  and standard de viation for  the BBS  IIC for the intended 
target of 56 subject s is less than 0. 9, the proposed sample size for the study may be increased.  
2. If the o bserved  mean IIC is less than 3, the study may be stopped for futility , since this differ-
ence is o f no clinical relevance.  
3. If the power based on o bserved mean and standard dev iation for the BBS IIC with the in terim  
analysis cohort of at least 35 sub jects is greater than 0.95, hypothesis test ing will be per-
formed  at the alpha  = 0.02 lev el to determine statistical significance. In this case, the primary 
objective wi ll be analy zed at the 0 .03 level for the final analysis of the full study cohort at the 
complet ion of th e study  to maint ain an overall Type I error rate of 5%. If the power is less than 
0.95 , hyp othesis testing will only be performed  at the conclusion of th e study and statis tical 
significance determ ined using  alpha = 0.05.  
 Cond itional hy poth esis testing may be performed for select  second ary objectives using the same 
method descri bed in rule 3 above. 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 60 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 11 Risk and benefit of the investigation device and clinical investig a-
tion  
C-Brace  is a CE -marked class I medical device. Risk analysis has been co nducted and identified risks 
such as blocking of flexion in knee joints when descending stairs or ramps, uninte ntional  locking 
during sitting, flexion resistance is not reduced when walking on level ground (swing phase), insuf-
ficient extension of knee joint in the stance phase, insufficient extension of the orthosis during standing up. All those identified risk could lead  to a fall. After implement ation of appropriate 
measures, the risk analysis concluded that the remaining risks are either acceptable or AL ARP (as 
low as reasonably pract icable).  
 In this clinical stud y, patients will be rand omly assigned to two treatment groups. Treatment group 1 
will start with 3 months usage of the patients’ KAFO or SCO. The patients will then move to a 3 -
month period of C -Brace  use. Treatment group 2 will start with 3 months of C -Brace use and will then 
enter into a 4 -week washout  period  before moving to a 3 -month period of KAFO/SCO use. This ran-
domization will not add any additional risks to the patients since both groups  will use both devices 
for the same period . 
 
Patients enrolled  in the study will enter  with their current orthosis (KA FO/SCO). Before performing 
the clinical tests, patients will receive up to 10h of accommodation training and will be bench-
marked according to their ability to use their orthosis. When entering the C -Brace  group, patients wil l 
again receive up to 10h of accommodation support and an assessment. Patients enrolled in the study who will start with C -Brace , will receive accommodation support and a ssessment. When switching 
back to their regular orthosis (KAFO /SCO) they will again receive accommodation and assessment. 
Therefore, the risks due to switching of the devices in the clinical study  are mitigated.  
 
The expected benefit of C -Brace  to the pati ents participating in this study w ill be comparable to the 
ones published on C -Brace . The literature published on C -Brace  suggests that microproces sor con-
trolled SSCOs offer benefits during walking on level ground, stairs and ramps when compared to convent ional KAFOs such as locked KAFOs and SCOs. Biomechanical ana lysis showed that more 
physiological swing and stance phase du ring level walking is possible with C -Brace  (Schmalz 2016). 
Walking on ramps and stairs was also more physiological allowing step -over -step descent. The load 
on the contralateral limb was reduced. C -Brace  also resulted in improved safety and reductio n in dif-
ficulty of performing activities of daily living (Pröbsting 2016). Subjects report of 91% of the ADLs being safer and 76% of the ADL s less difficult to perform with C -Brace  in comparison to th eir previ-
ous orthosis. Gr eatest functional gain was achi eved in the categories Family and Social Life and 
Sports and Leisure activities. Signif icant improvements were achieved in the domains of am bulation, 
paretic limb health, well -being and disturbing sou nds of the ortho sis. 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 61 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
  
The new version of C -Brace  is smal ler and reduced in weight. Furthermore, due to an improved sen-
sor sy stem in the joint unit, sensor at the ankle become obsolete and therefor e the design of the or-
thotic shells can be better adapted to  the individual anatomy. Therefore, the benefits of the new C -
Brace  should be better or at least in the range of those r eported for the original C -Brace . The sensor 
technology that does not requir e an ankle sensor is already applied in the C -Leg 4. First c linical re-
sults showed hi gh satisfaction (94% of users r eported to be either satisfied or very satisfied) and 72% 
of users reported better or much better swing initiation compared to their previou s prosthesis (Kraft 
2015, Wismer 2016).  
 Therefore, it can be concluded that the ris ks associated with the use of t he device are accept able 
when weights against the benefits that this research can generate in terms of further deve lopment of 
C-Brace  to the  subjects and patient population in general.  
 Risk -benefit assessment of the clinica l investigation during the COVI D-19 pandemic situation  
 In this clinical study, patients are asked to visit the study site for 6  visits, as well as for additional 
visits if required by the site for the purpose of fitting of assisti ve devices (KAFO/SCO or C -Brace) . In 
most likely all cas es, patients will have to travel to get to the respective study site.  
 All patient appointments will be done in accordance with the effecti ve national , state  and local regu-
lations on contact and /or travel restrictions due t o the COVID -19 pandemic. Whenev er possible, the 
number of appointments at the study site will be reduced and patient assessments will be managed 
over the phone (unless the patient needs assistance with their medical device).  
 Prio r to arriving to the firs t visit since the  start of the COVID -19 pandemic,  a risk factors assessment 
shall be conducted in accordance with the procedures valid in the sites in order to decide whet her 
the patient should attend the next visit at the site (i.e. to continue in the stu dy for patients already 
enrolled or to attend an enrollment visit for patients interested in participating in the study).  
 
During patient visits, every effort will be tak en to minimize a potential infection risk by:  
• limiting the number of staff to a mini mum,  
• providing sufficient protection material to the patients as well as to the staff (gloves, coats, 
face masks , hand hygiene practices, cleaning of assistive devices and  surfaces, and other pre-
cautions that will be taken before and after every patient vi sit),  
• minimizin g the length of stay necessary for the patients and  
• maximizing the distance between patients and staff as much as possible.  
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 62 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 In case of increasing health risk or for any other reason, all enrolled s ubjects may  withdraw from the 
study at a ny time.  
 
Theref ore, it can be concluded that, given that all mitigation measures described above are taken, 
the risks associated with a study visit during the COVID -19 pa ndemic are acceptable when weig hed 
against  the benefit s that this research can genera te for the individual and the population in general.  
 
If the study is still running after the COVID -19 pandemic situation, some of the precautions will not 
be necessary anymore. In this case, potential  subjects will be invited to attend an information meet-
ing with the Principal Investigator (PI). If the subject is considered by the PI to be eligible for partici-
pation in the study, he/she will be fully informed about the stu dy and given sufficient time t o con-
sider and given an opportunity to ask questions or  to discuss participation with his/her general prac-
titioner or therapist. Subjects who wish to enter the trial will then sign the consent form and subse-
quently be enrolled . 
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 63 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 12 Management of adverse even ts 
 
12.1 Description of possible adverse events & adverse de vice effects  
Falls  are expected to be reduced in general using a C -Brace , however in patient s with limb impair-
ment falls might occur.  
 
12.2 Definitions  
 
The investigator is res ponsible for recording all AEs  diagnosed in the frame of study visits, reported 
by th e participant or communicated to the investigator by a third person during the study period.  
Adverse Event  
An AE is ( acc. to  ISO 14155- 2020 ) any untoward medical occurrence, unintended disease or i njury, 
or u ntoward clinical sign (including abnormal l aboratory findings) in patient s, users or other per-
sons, whether or not related to the investigational medical d evice  
 
A Serious Adverse Event (SAE) is an Adverse Event that  (acc. to ISO 14155 -2020 ): 
1. led to a death;  
2. led to a serious deterioration in the health of the patient  that  
- results in a life -threatening illness or injury;  
- results in a permanent impairment of a body structure or a body function;  
- requires hospitalization or prolongation of existi ng hospitalization;  
- results in medical or surgical inter vention to prevent permanent impairment to body struc-
ture or a body function; or led to  
3. fetal distress, fetal death or a congenital abnormality or birth defect. (Ref ISO/DIS 1 4155-
2020)  
Adverse  Device Effects (ADE):  adverse event related to the use of an inves tigational medical device. 
This i ncludes adverse events resulting from insufficient or inadequate instructions for use, deploy-
ment, implant ation, installation, or operation, or any malfun ction of the investigational medical de-
vice, as well as, a ny event resulting from use error or from intentional misuse of the investiga tional 
medical device (Ref ISO/DIS 14155 -2020 ). 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 64 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Serious Adverse Device E ffect (SADE):  adverse device effect that has resulted in any of the conse-
quences cha racteristic of a serious adverse e vent.  (Ref ISO/DIS 14155 -2020 ) 
Unanticipated Serious Adverse Device Effect (USADE):  serious adverse device effect, which by its 
nature, inc idence, severity or outcome has not been i dentified in the current version of the risk anal-
ysis re port (Ref ISO/DIS 1 4155 -2020 ). 
Device deficiency  represents inadequacy of a medical device with respect to its identity, quality, du-
rability, reliability, safety or performance. Device deficiencie s include malfunctions, use errors, and 
inadequate label ing (Ref ISO/DIS 14155 -2020).  
 
12.2.1  Additional national definitions  
Germany  
Notwithstanding the definitions in ISO/DIS 14155- 2020, the following definitions apply according 
to Medizinprodukte Sicherh eitsplanverordnung (MPSV) and have to be used for categorization of 
AEs and SAEs in G ermany:  
 
According to §2 (5) MPSV a serious adverse event is "... any unintentional event occurring in a clini-cal trial or performance evaluation subject to authorization  which has led, could have led or could 
lead directly o r indirectly to the death or serious deterioration of the state of health of a subject, user 
or other person without taking into account whether the event was caused by the medical device; the 
foregoi ng applies mutatis mutandis to serious adverse events th at have occurred in a clinical trial or 
performance evaluation for which an exemption from the licensing requirement pursuant to § 20 (1) 
sentence 2 of the “Medizinproduktegesetz" has been granted.  
According to §2 (1) MPSV an event is "... a malfunction, a  failure, a change in features or perfor-
mance or an improper labelling or instructions for use of a medical device, which has led, could have 
led or could lead directly or indirectly to the death or s erious deterioration of the state of health of a 
patient , user or other person; a malfu nction is also considered to be a lack of fitness for use, which 
causes misuse.".  
 
Netherlands  
Definitions for AE/SAE in the Netherlands follow the definitions in MEDDEV  2.7/3 rev.3 which are in 
line with the definitions in I SO 14155 2020 . Therefore, no na tional definitions for AE/SAE are neces-
sary.  
 
United States of America  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 65 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Definitions for AE/SAE in the US follow the definitions in ISO 14155. Therefore, no national d efini-
tions for AE/SAE are necessary.  
 
Austria  
Notwithstanding the definitions of ISO14155 -2020, the following definition applies according to the 
Austrian “Medizinproduktegesetz”:  
Austria §2(17) MPG: Adverse Device Effect ("Nebenwirkung") is any u ndesirab le cl inical event occur-
ring under and related to the nor mal conditions of use of a medical device, i.e., a device- related ad-
verse event.  
 
12.3 Documentation  of Adverse Events  / Serious Adverse Events  
 All AEs are to be recorded once only on the appropri ate AE p ages in the CRF. The investigator should 
complete all the details r equested including dates of onset, severity, corrective therapies given, out-
come and opinion as to whether the AE is likely to be device- related. Each event should be recorded 
separ ately.  
In th e case of a SAE , the investigator must complete, si gn and date the SAE pages from the CRF, 
check that the data are consistent, and send a copy  without any further delay  to the contact speci fied 
below : 
 
Ottobock SE & Co. KGaA, Max -Näder -Str. 15 , 37115 Duder stadt  
Fax: +49 5527 848 -83402 
   
Where additional follow -up information is required, this should be completed on a SAE follow -up 
form, a copy sent to the Sponsor and the original placed in the SAE section of the CRF.  
12.4 Reporting of Adverse Eve nts / Ad verse  Device Effects  
 
During the entire patient follow -up period, any AE or ADE that occurs to a person during the study 
period must be followed until it resolves or is deemed perm anent. Any AE  or ADE , regardless of 
whether it is related to the stu dy, must  be d ocumented. Any SAE  (device/procedure- related or not  
device/procedure- related) must be reported  to the sponsor on the form provided for this purpose in 
the case report form without any further delay from the moment of occurrence (or as soon as the in-
vestiga tor becomes aware of it). The initial report  may be  followed by relevant additional i nformation 
within 7 days.  
In the case of SAE and SADE, sponsor and investigator together complete the reporting forms for Eth-
ics Co mmittee(s) and competent au thority.  Both  sponsor and investigator evaluate the causal rela-
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 66 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 tionship between the AE and investigational device and if different note this on the form. After sign-
ing the forms, either sponsor or investigator forwards it to the Ethics Committee and regula tory au-
thorit y, if applicable. In case of multicen ter and/or mul tinational studies, the sponsor has responsi-
bility to inform other centers and relevant Et hics Committees / authorities.  
12.4.1  Additional national requirements for reporting of adverse events  
Germa ny 
Notwi thsta nding the definitions in ISO/DIS 14155- 2011 , the fo llowing definitions apply according 
to Medizinprodukte Sicherheitsplanverordnung (MPSV) and have to be used for reporting AEs and 
SAEs in Germany:  
After the sponsor has received a notification of an S AE th at cannot be ruled out as being related to 
the medi cal device under investigation, a reference product or the therapeutic or diagnostic 
measures applied in the clinical trial or the other conditions for conducting the clinical trial, this must  be repo rted to the responsible competent authority (BfArM) without further delay. The follow-
ing form must be used for this purpose:  
https:// www.bfar m.de/ SharedDocs/Formulare/DE/Medizinprodukte/Meldeformul ar_Klinische-
Pruef_SAE.html  
All other SAEs for which a connection with the medical device under investigation, a reference prod-uct or the therapeutic or diagnostic measures applied in the cli nical tr ial o r the other conditions for 
conducting the clinical trial can be ruled out must be reported to the competent authority (BfArM) on 
a quarterly basis. The following form must be used for this purpose:  
http://ec.europa.eu/DocsRoom/documents/16477/ attachme nts/2 /translations  
If an SAE occurs in the context of a clinical study with a CE -certified medical device in which a con-
nection with the test product cannot be ruled out, this must be reported immediately to the compe-
tent authority (BfArM) as an "i ncident"  in a ccordance with Sections §3 and §5 MPSV as soon as i t 
becomes known. If a serious undesirable event also constitutes an incident, the sponsor may also fulfil its obligation to report the incident by submitting an SAE report in accordance with § 3 (5) 
MPSV. I n the report it must be made clear that the obligat ion to report an incident in accordance with 
§3 (1) MPSV is also fulfilled.  
Netherlands  
The sponsor must immediately inform the Inspectorate (within two working days and not later than four ca lendar d ays) of SAEs which indicate an inevitable risk of death,  serious injuries or serious ill-
ness, and requiring prompt remedial action for patients.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 67 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 This includes SAEs that result in (temporary) suspension of inclusion of patients in the clinical inves-
tigation , dis continuation of the clinical investigation (tempora rily or otherwise), or modification of 
the medical device.  
Events that were reasonably foreseeable and are described as such in the Protocol and the patient information (“calculated risks”) ar e exclud ed fr om the above requirements, insofar as they do not 
lead to the (temporary) suspension or discontinuation of the clinical investigation or to modification 
of the medical device.  
MEDDEV 2.7/3 stipulates that all other reportable events (see secti on 4 of MEDDE V 2.7/3) must be 
reported within no more than seven days. The Inspectorate applies a less intensive term in this re-
spect. SAEs that do not fall under item 2 above may be reported quarterly in their totality to the In-spectorate by means of the reportin g tab le, which can be found on the website of the European 
Commission.  
Austria  
The sponsor of a clinical investigation has to fully record all serious adverse events and notify them immediately to the BASG and to all other competent authorities in those member states of the EEA in 
whic h the clinical investigation is being performed.  
Note:  
• Where a medical condition is already established prior to the initiation of a clinical investigation  
and surgery has been scheduled to amend it,  the definition o f an adverse event according to 
MPG is not fulfilled and reporting to the BASG as SAE is not required. If the medical condition 
arises during the conduct of the clinical investigation, then SAE reporting to the BASG is re-
quired  
• If a hospi talization preced ed or was alre ady planned prior to the initiation of a clinical in vestiga-
tion the definition of adverse event according to MPG is not fulfilled, no reporting as SAE is re-
quired. However, if unplanned hospitalization occurs during the condu ct of the clinical investi-
gatio n, SAE reporting to the B ASG is required -  whether or not causality has been established 
with the investigated device.  
 
SAE and SADE that result in immediate risk of death, serious injury or illness will be reported with-
out delay, at least within 2 calend ar days to EK and BASG. A ll other SAEs and SADEs will be reported 
by sponsor within 7 days.  
All incidents (Zwischenfall) will be reported by sponsor to competent authority (BASG) and ethics 
committee as specified in MPG §70(1 ) MPG.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 68 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
  
13 Monitori ng  
The Clinica l Project Manager will ensure proper monitoring of the study with special attention to ver-
ification of all clinical requirements, adherence to protocol, good clinical practices and co mpliance 
with applicable government  and in stitutional regu lations.  
Author ized, qualified represent atives of the sponsor or authorized, qualified staff of a CRO commis-
sioned by the sponsor will visit the investigational site in regular intervals to verify the adherence to 
the clinical investigation plan and local legal requirements, to perform source da ta verification and 
to assist the investigator in his study related activities.  
The monitor will at least document protocol deviations to informed consent procedures, SAE report-ing within required tim elines and inves tigational prod uct handling in the Proto col Deviations Log. 
The Protocol Deviations Log will be consecutively completed during the ongoing trial as an appendix to the Monitoring Visit Report. Protocol deviations detected by data management should be notifi ed 
to the spons or and to the monitor. Th e monitor or the data management will notify the investigator of 
deviations in writing.  
The following visits are planned: site qualification and feasibility, site initiation, routine vi sits and 
closeout  visit. More details are giv en in the Monitoring Plan.  
Monitor is responsible for reviewing the data for completeness and clarity. The details are provided 
in the Monitoring  Plan. The investigator(s) commits to allowing audits to be performed by the sp on-
sor and to p otential inspecti ons being performed by co mpetent authorities. All data, documents and 
reports can be suspect to audits and regulatory inspec tions.  
13.1 Direct Access to Source Data/Documents  
The investigator will permit study -related monitoring, audits, EC revie w and regulator y inspections 
and provide  access to primary data  (i.e. source data) which supports the data on the CRFs for the 
study, e.g. general practice charts, hospital notes, appointment books, original laboratory records to 
sponsor, authorized repres entatives of the sponsor such as study monitors and auditors, and appro-
priate regulatory authorities.   
Any party with access to study records shall take all reasonable precautions consistent with applica-ble regulatory requirements to maint ain the confidentiality of pati ent identifying informati on and 
sponsor’s confidential and/or proprietary information.   
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 69 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 13.2 Source Documents and Source Data  
Source documents are defined as printed, optical or electronic documents containing source data 
(e.g. hospital records,  laboratory not es, device accountability  records, photographic negatives, radi-
ographs, records kept at the investigation site, at the laboratories and at the medico -technical de-
partments involved in the clinical investigation) (ISO 14155: 2020).  
The eCRF is  used as source data.  
 
14 Data manage ment  
Data collection  
A web -based standardized electronic case report form (eCRF) (eClinicalOS IBM 2.0) and a paper -
based CRF will be used to document the patients’ data during the course of the study.  Both CRF s are 
designed to accommodat e the specific feat ures of the study design. All data obtained after the patient 
has given informed consent must be recorded in the CRF s. The investigator will assure that all data 
are entered promptly, completely, and accurately according t o the CRF instr uctions, and confor m to 
source documents. Data for all patients screened for study inclusion have to be documented on a 
respective form.  
The eCRF and a paper -based CRF are  used as source data.  
Case Report Forms ( CRFs ) must be co mpleted after  every visit fo r each patient  enro lled into the study  
within 4 weeks . 
Only investigators and authorized designees are allowed to make entries in the CRF. This will be reg-ulated by appropriate reading and writing access. Completed CRFs  per visit, must be el ectronically 
signed by the investi gator or authorized designee. Any change or addition will be recorded by an au-
dit trail system.  
All forms must be filled out completely;  data are checked electronically for consistency and plausi-
bilit y.   
It is the investi gators’ obligat ion to assure docum entation of all relevant data in the patient’s file, 
such as medical history, concomitant diseases, date of study enrolment, visit dates, results of exami-
nations, administrations of medication, and AE s. 
Worksheets are allo wed as back up, information must be  entered electronically.  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 70 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Self-reported patient questionnaires are filled out by patient. Investigator checks when he receives 
the ques tionnaires back, if they are completed and refer to the patient to  complete missing item s if 
applicable .  
Data management procedures  
All data management activities will be conducted by the sponsor or a sponsor’s designee following 
their SOPs. The database will be built by the sponsor or a sponsor’s designee.  
Details on d ata handling will be d escribed in the Data Management Pl an. The sponsor or the spon-
sor’s designee will handle the data cleaning process, including logical check, and query processes. 
Computerized validation check programs on completeness, correctness, plau sibility (such as rang e 
checks, cross checks ) will verify  the data according to the Data Validation Plan. All identified dis-
crepancies will be addressed to the investigator.  
The database will be hard locked after all the changes following the data review meeting have been 
done a nd the database is considered comp lete and accurate. All changes will be tracked (audit trail).  
 
15 Documentation and administration  
15.1 Investigator’s Brochure  
The investigator shall be informed by means of the Investigator’s Brochure on t he preclinical and 
clinical state of knowledge concerning the Investigational Product. In so far as important new infor-
mation arises,  the information for the investigators will be updated on a regular basis.  
15.2 Deviations from Clinical Study Protocol  
A clinic al study protocol devi ation is any in stance of failure t o follow, intentionally or unintentional-
ly, the requirements of the clinical study protocol (ISO 14155: 2020).  
Ottobock is responsible for analyzing deviations, assessing their significance, and i dentifying any 
additional corrective and/ or preventive a ctions (e.g. amend the clinical study protocol, conduct addi-
tional training, etc.). Repetitive or serious investigator compliance issues may require initiation of a corrective action plan with the inv estigator, and in some cas es, necessitate suspending sit e enroll-
ment until the problem is resolved or ultimately terminating the investigator’s participation in the study.  
Major clinical study protocol deviations represent non- adherence to one or more incl usion and/or 
exclusion cri teria or are co nsidered to aff ect the safety and well -being of the patient. Major clinical 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 71 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 study protocol deviations increase the risk, decrease the benefit and/or affect the participant’s rights, 
safety, and/or the integrity of t he resultant data. They al so may result f rom evidence of  willful or 
knowing misconduct on the part of the investigator, or from ignorance of established research, med-
ical, and ethical principles.  
Examples for major deviations:  
• Patients  enrolled prior to  EC notification of approv al or after exp iration of appr oval  
• Enrollment  of a patient outside the inclusion/exclusion criteria  
• Use of an unapproved or expired informed consent form  
• Inadequate/improper  informed consent procedures  
• Inclusion of pat ients who have not provide d written consent  
• Failure  to maintain adequate patient records or proper study documentation 
It is the responsibility of the Investigator not to deviate from the protocol approved by the EC, except 
as necessary to avoid an imme diate hazard to the partic ipant.  
 
Proced ure:  
Should a d eviation from the clinical study protocol be deemed crucial for the safety and well -being of 
a particular patient, such a departure will be instituted for that patient only. The Investigator should 
document in the patient’s CR F and in the pa tient´s medical  file the reason(s) for the deviation. Each 
participating center must adhere to the policies and guidelines established by their EC for the fre-quency and format of reporting clinical study protocol deviations.  
Major clinical study protocol deviations are to be reported to the study Sponsor as soon as the Inves-
tigator or study personnel become aware of their occurrence.  
Clinical study protocol deviations will be documented and reported at the time of continuing review 
report.  
 
15.3 Amendments to t he Clinical Stu dy Protocol  
All amendments to the clinical study protocol should be agreed between the Sponsor and the Inves-
tigator and be recorded with a justification for the amendment. The Investigator or the Spon sor will 
not implement any  deviation from , or changes of , the clinical study protocol without mutual agree-
ment and review/approval from the EC, and other agencies as required, of a proposed amendment. The only exceptions are where necessary to eliminate an immediate safety hazard t o study patient s, 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 72 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 or when the changes involve only administrative aspects of the clinical study (e.g. change in moni-
tor(s), change of telephone number(s)).  
The party initiating an amendment must confirm it clearly in writing and i t must be signed and dated  
by the Sponsor , the Coordinat ing Investigator and the Principal Investigators. Clinical  study protocol 
amendments will be submitted to the appropriate ECs and competent authorities in line with perti-
nent national regulatory requi rements.  
 
15.4 Final Report  
After the statisti cal analysis,  the final report for the study is prepared and has to be signed by the 
study coordinating investigator, the principal investigator s and  the sponsor.  
 
16 Study Discontinuation  
16.1 Investigational Site Terminat ion 
Otto Bock Healthcare P roducts GmbH re serves the right to terminate an investigational site for any of 
the fo llowing reasons:  
• Failure to secure Informed Consent from a patient  enrolled into the study  
• Repeated protocol devi ations  
• Repeated failure to comp lete Case Record Forms on a timely basis  
• The investigato r requests discontinuation  
If the study is prematurely terminated or suspended for any reason, study participants will be in-
formed promptly and, where required by the applicable regulatory requirement (s), the relevant regu-
latory author ity(ie s) will be info rmed. The ethics committees will be informed promptly and provided 
with a de tailed written explanation for the termination or suspension . 
 
16.2 Premature discontinuation of the complete study  
If the study is prematurely terminated or suspended, t he Project Mana ger, on behalf of Otto Bock 
Healthcare Products GmbH, will inform promptly the investigator/institution, and, if applicable, the regulatory author ity(ies) of the termination of suspension and the reas on(s) for the termination or 
suspension. The ethics co mmittees will be informed promptly and provided with a detailed written 
explanation for the termination or suspension by the Project Manager, on behalf of Otto Bock Healthcare Products GmbH, or by the i nvestig ator/institution, a s specified by the applicab le regula-
tory requirement(s).  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 73 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Some of the reasons for premature termination of the study are:  
• If the safety of the participants is jeopardized (eh. many falls and stumbles reported), a nd 
• If the users ca nnot  show “proficient use”  of the interve ntion devices.  
 
Please see section  18 for publication strategy  after premature discontinuation.  
16.3 Requirements for patient follow up  
In case of premature discontinuation of the study, the study site will contact the patients enrol led in 
the study. The pati ents wi ll return the C -Brace o rthosis to the study center. To ensure a safe use of 
their current orthosis (KAFO/SCO), patients will get an accommodation support and will be assessed 
for their orthosis use by a CPO or PT. Since thi s orthosis represents thei r ortho sis before entering in 
the study, no additional risk for the patient is assumed.   
In case of premature discontinuation of the study, available study data can be used to support a re-imburs ement application according to loca l regul ations for the time after the study. If such an a ppli-
cation is filed, the device may remain with the patient until reimbursement is granted but for a max-imum of 24 months.  Patients will be re- trained or re -accommodated . All procedures des cribed in sec-
tion 7.3.10 will apply.  
17 Ethical  considerat ions  
17.1 Independent ethics committee   
In accordance with current laws of the countries where study will be conducted, the protocol will be submi tted to the Research Ethics Committee for an opinion. The s tudy will start once approved the 
study and a uthor ities,  if applicable . Any necessary extension or r enewal of the ethics committee ap-
proval must be obtained. C hange(s) to any aspect of the trial, such as modification(s) of the protocol, 
the written informed consent form, the written informati on provi ded to patients, and/or ot her proce-
dures must be approved, in writing, by the ethics committee.  
 Ethics committee will be informed promptly of any new information that may adversely affect the 
safety of patient s or the conduct of the trial. Similar ly, any written sum maries of the trial status will 
be reported to the ethics committee annually, or more frequently, if r equested by the ethics commit-
tee. Upon completion of the trial, the ethics committee with be provi ded with a study  report.  
17.2 Ethical cond uct of t he s tudy  
The Guidelines of the World Medical Association Declaration of Helsinki, the Guidelines of GCP, and 
ISO 14155 -2020  as well as the demands of national drug and data protection laws and other appli-
cable regulatory r equirements will be strict ly follo wed 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 74 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 The investigator(s) must fulfil l all requirements as stated in ISO 14155 -1 and national law. He/she is 
responsible for the co nduct of the clinical trial and is responsible for the clinical well -being of  the 
patient s involved.  The investigator(s ) is not  allow ed to deviate from the CIP.  Request for changes 
needs to be first di scussed with the sponsor who will if required request permission from the Et hics 
Committee.  In case,  deviation was not possible to omit (i.e. to protect rights, safety, well -being o f 
patients), they need to be documented and reported.    
The sponsor must fulfil l the requirements and responsibilities as stated in ISO 14155 -1 and natio nal 
law.  
 
17.3 Patient information and informed consent  
The investigator is responsible for ensuring that n o patient is patient  to any study -related examina-
tion or ac tivity before that patient  and/or legal guardian has given informed consent. Written con-
sent must be given by the patient , after the receipt of det ailed information. The verbal explanation 
will cov er all  the elements speci fied in the written information provided for the patient .  
 
The investigator will inform the patient  of the aims, methods, anticipated benefits and potential haz-
ards of the study in cluding any discomfort it may en tail. The patient  must b e given every opportunity 
to clarify any points he/she does not understand and if neces sary, ask for more information. At the 
end of the interview,  the patient  may be given time to reflect if this is required, or more time for dis-
cussion with  family,  care givers  or their own General Practitioner. Patient s and/or legal guardian will 
be required to sign and date the informed co nsent form. After all pa rties have signed and dated the 
informed consent, a cop y will be given to the patient s while the original  will be kept and archived by 
the i nvestigator.  
 It should be emphasized that the patient  is at liberty to withdraw their consent to participate at any 
time, without penalty, loss of benefits or normal med ical care to which the patient  is otherwise enti-
tled. Patients who refuse to give  or withdraw written informed consent may not be i ncluded or con-
tinue in this study.  
 COVID -19 Risk Factors Assessment  and patient re -consent  
Prior to arriving to a study site  for the first visit since the start of the  COVID -19 pan demic (i.e. first 
visit at the site  for patients  not yet enrolled , or follow -up visit for patients  already enrolled ), an in-
formed consent form will be sent to the patient per mail  or email. After havi ng received the informed 
consent form, the investi gator will contact individual patient via phone to conduct the informed con-
sent process. A  patient who decides to continue in the study or remains interested  in enrolling  in the 
study will be asked to provi de his/her consent verbally. Following verb al cons ent, t he investigator 
will perform a risk assessment  with the patient via phone. During this assessment the patient will be 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 75 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 asked about his/her exposure to COVID -19 (i.e. potential contact with infected sub jects, potential 
COVID -19 test) along with  other general  health questions (i.e. age, lung disease, kidney disease, 
cancer, obesity) known to be placing the patient at an increased risk in accordance with those identi-
fied by  the Robert Koch Institute (RKI) (G ermany ), , National I nstitute for Public Health  and the Envi-
ronment  (The Netherlands) , Federal Ministry Republic of Austria, Social Affairs, Health, Care and 
Consumer Protection (Austria) . If no risk factors are identified and the patient is willing to continue 
or to enroll in  the study, an appoi ntment will be made for an on -site study visit . In case the investiga-
tor identifies one or more risk factors during the phone contact, the decision to continue or to enroll 
in the study will be deferred to the site P rincipal Investigato r. At the on- site st udy vis its, subjects  en-
rolling or agreeing to continue with the study will physically sign the IRB-approved  informed con-
sent form.  
 
17.4 Patient insurance  
Ottobock has taken out patient  insurance with Allianz Global Corporate & Specialty SE  for all pa-
tients tak ing par t in the trial under the policy number DEL007668190, NLL001051190 and 
ATL001224210 . 
All investigators shall receive a copy of the insurance certificate and the insurance conditions; the latter must be known to the patients and ma de available on requ est.   
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 76 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 18 Disclosure of data and p ublication p olicy  
The data generated in this study as well as the results of the study, are the property of the sponsor. 
The aim and contents of the clinical study, in addition to its results are to be t reated as confidenti al 
by a ll persons involved in the clinical study.  
No publication, disclosure, or any other use of the results of this study are allowed without prior written permission of the spo nsor. Any publication is based on the final report appro ved by Ot-
tobock. The  invest igator will receive a copy of the final report. Thereafter the manuscript for joint 
publication can be drafted. A joint publication of the results should be made in mutual a greement. 
All editorial decisions are taken jointly by O ttobock and the investigato rs. Ottobock  is entitled to 
check a draft for publication latest 60 days before submission, and to advise within 60 days any nec-essary reasonable supplements.  
Ottobock is en titled to utilize all relevant data of the study for registration purposes, worldwi de sci-
entific product documentation and for publication.    
In case of a premature determination of the study, the publication strategy will be discussed and 
agreed between the sponsor and the investigators. Possibilities include i.e. to decide not to publ ish 
the study results.   
  
19 Retention of records  
Essential clinical investigation documents, as defined in ISO 14155- 2020, are to be retained by the 
investigator during  the clinical investigation and for the period required by the applicable regulato ry 
requ irements or for at least 15 years after the premature termination or completion of the clinical 
investigation, whichever is the longer. However, the investigator shoul d contact the sponsor prior to 
destruction of any record s or reports pertaining to  the cl inical investigation in order to ensure they 
no longer need to be retained. In addition, the sponsor should be contacted if the investigator plans to leave the site so  that arrangements can be made for transfer of records.  
The medical files of study  patien ts must be retained in accordance with local legislation and in ac-
cordance with the maximum period of time permitted by the hospital, institution or private practice.  
Sponsor and principal investigator shall take measures to prevent accidental or p remature destruc-
tion of these documents. The principal investigator or sponsor may transfer custody of records to 
another person/party and document the transfer at the invest igation site or at the sponsor's facility.  
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 77 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 20 Study timeli ne  
First Patient first Vi sit pla nned: 1st Mar 2019.  
Last Patient last Visit planned: 31 Dec 202 2 
 
Observational period per patient: 8 to 9 months depending which orthoses is used before cross -over 
Given the impact of the COVID -19 pandemic, the observational period per patient m ay incr ease by 
additional 6 to 7 months.  
Final report: 30 Jun 202 3 
 
21 Publication Plan  
Please see section 18 for det ails regarding publication of study data. 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 78 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 22 References  
1 Center for Disease Control and Preventi on. Nat ional Health Interview Survey. Table 1a. Number of pe rsons 
using assistive technology devices by a ge of person and anatomical device: United States, 1994.  Accessed 
9/17/13 from http://www.cdc. gov/nchs/nhis/ad292tb1.htm  
(American publication was used to estimate patient numbers for Germany).  
2 Hebert JS, Adrian BL, Eng P. Gait evaluation of an automa tic stance -control knee orthosis in a p atient with 
postpoliomyelitis. Arch Phys Med Rehabil. 2005;86:1 676-1680.  
3 Arazpour M, Bani MA, Hutchins SW, Jones RK. The physiological cost index of walking w ith mechanical 
and powered gait orthosis in patients wit h spinal cord injury. Spinal Cord. 2013;51:356 -359 
4 Davis PC, Bach TM, Pereira KM. The effect  of sta nce control orthoses on gait characteristics and energy 
expenditure in knee -ankle -foot orthosis us ers. Prosthet Orthot Int. 2010;34:206 -215. 
5 Yakimovich  T, Lemaire ED, Kofman J. Gait evaluation of a new electromechanical stance -control knee -
ankle -foot orthosis. Proceedings of the 28th IEEE EMBS Annual International Conference New York City, 
USA, Aug 30-Sept 3, 2006. Accessed on PubMed: PMID: 17946729  
6 Yakimovich T, Lemaire ED, Kofman J, Eng P. Engineering design review of stance -control knee -ankle-foot 
orthoses. Journal of Rehab Res & Devel. 2009;46(2):257 -268. 
7 Sykes L, Ross ER, Powell ES, Edward s J. Objective measurement of use of the reciprocating g ait orthosis 
(RGO) and the electrically augmented RGO in adult patients with spinal cord lesions. Prosthet Orthot Int. 
1996;20(3):182 -190. 
8 Berg KO, Wood -Dauphinee SL, Williams JI, Maki B. Measuring  balance in the  elderly: validation of an in-
strument. Ca n J Public Health. 1992 Jul -Aug;83 Suppl 2:S7-11. 
9 Shumway -Cook A, Baldwin M, Polissar NL, Gr uber W.  Predicting the probability  
for falls in community -dwelling older adults. Phys Ther. 1997 Aug;77(8 ):812 -9 
10 Hafner BJ, Willingham LL, Buell NC, Allyn KJ , Smith DG. Evaluation of function, performance, and prefer-
ence as transfemoral amputees transi tion from mechanical to microprocessor control of the prosthetic knee. 
Arch Phys Med Rehabil. 2007;88:207 –17. 
11 Schwenk M, Lauenroth A, Stock C, Moreno RR, Ost er P, McHugh G, Todd C, Hauer K. Definitions and 
methods of measuring and reporting on injurious falls  in randomised controlled fall prevention trials: a sys-
tematic review. BMC Med Res Methodol. 2012 Apr 17;12:50. doi: 10.1186/1471 -2288 -12-50 . Review  
12 Wood -Dauphinée SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assess -ment of global func-
tion: T he reintegration to normal living index. Arch Phys Med Re -habil 1988;69:583 -90. 
13 Stark SL, Edwa rds DF, Hollingsworth H, Gray DB. Validation of the rein tegration to normal living index in a 
population of community -dwelling people with mobility limitations. Arch Phys Med Rehabil 2005;86:344 -5. 
14 Lerner D, Amick BC 3rd, Rogers WH, Malspei s S, Bungay K, Cynn D. The Work  
Limitations Questionnair e. Med Care. 2001 Jan;39(1):72 -85. 
15 Heinemann AW, Bode RK, O’Reilly C. Development and measurement prope rties of the Orthotics and Pros-
thetics Users’ Surve y (OPUS): A comprehensive set of cl inical outcome instruments. Prosthet Orthot Int. 
2003; 2 7:191 -206. 
16 Jones, Byron; Kenward, Michael G. (2015): Design and analysis of cross -over trials. 3. ed. Boca Rat on, F la.: 
CRC Press (Monographs on statistics & applied probability, 138).  
17 Jenniso n, Christopher; Turnbull, Bruce W. (2000): Group sequent ial methods with applications to clinical 
trials. Boca Raton: Chapman & Hall/CRC  
 
 
 
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 79 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 23 Appendix  
23.1 Appendix I: Procedu re fo r device read -outs  
 
• Setup App  
A pdf-export of the Setup  App will be taken by the CPO at definitive fitting , every time a change i n 
the settings is done and at the follow -up visits. The file  shall be stored according to the following 
convention:  
Export ing p rogramming data from the C -Brace Setup -App  
1. Launch the C -Brace  Setup -App 
2. Connect the mobile device and C -Brace via Bluet ooth 
3. Go to the menu and select “Data overview”  
4. Choose the 
 icon to export the data  
5. Use the following file name convention for the e xport  file: 
 
CB2-XX-ZZ-DDMMMYY  
 
Where  XX-ZZ is the Site ID and Patient ID and  
DDMMMYY  is the programming date  
 
6. Download the data file and  upload the file t o the eCRF.  
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 80 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 
 
Figure 5: Screenshot of the C -Brace  Setu p App 
 
• For C -Brace  the following read –  outs are collected from the SD -card of the joint unit at defini-
tive fitt ing as well as at  follow – up visit s 
 
• Steps with < 1.5 km/h  
• Steps between 1.5 and 2.5 km/h  
• Steps between 2.5 and 3.5 km/h  
• Steps between 3.5 and 4 .5 km/h  
• Steps between 4.5 and 5.5 km/h  
• Steps faster than5.5 km/h  
• Steps where the patient used stance phase flexion  
• How often did the patient sit down respectively  activated the sitting function?  
• Time in stance/standing function  
• Time in sit function  
• Time in Freeze Mode  
• Time in Training Mode  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 81 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 • Time in User -Defined Mode (MyMode)  
• Time in Standby (C -Brace  didn’t move  for >60s)  
• Battery charging time  
• Total Time of use (coun ts basically every after the fitting minus time of power -off) 
 
 
 
• Step Count  
A step count  transp onder will be fixed on C -Brace  and on KAFO/SCO. It will be read out after each 
obse rvational period.  
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 82 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 23.2 Appendix II: Study Overview (German)  
 
Sponsor  Otto Bock Healthcare Products GmbH  
Studientitel kurz  Klinische St udie zum Vergleich C -Brace  vs. KAF O/SCO  
Studienziel  Evaluierung der Effektivität und des Patientennutzens bei 
Patienten mit Beeinträchtigung der unteren Extremität 
hinsichtlich der Aktivitäten des tä glichen Lebens im Vergleich 
zwischen C -Brace , einer Mikroprozessorgesteuerten Stand - und 
Schwungphasen- kontrollierten Orthese und der 
Alltagsversorgung, einer KAFO/SCO    
Design Prospek tive, international e, multizent rische,  offene,  
kontrollierte , randomisierte  cross -over Studie  
Prüfpr odukte  C-Brace , KAFOs, SCOs  
Primärer Wirksamkeits-
endpunkt  Verbes serung der statischen und dynamischen Balance bei der 
Verwendung von C -Brace  im Vergleich zu KAFO/SCO   
  
Sekundäre Endp unkte 1. Evaluation des C -Brace  Effekts auf das Gangbild, die 
Balance, das Gehen auf ebenem Untergrund, das Gehen 
während erschweren der Au fgaben, sowie während  
Aufmerksamkeitsaufgaben im Vergleich zu K AFO /SCO .  
2. Best immung und Vergleich der sicheren Anwendung von C -
Brace  hinsichtlich der Parameter: Sturzhäufigkeit, Schwere 
der Stürze, Sturzassoziierte Verletzungen, Angst vor Stürzen und  damit  verbundener Behandlu ngsaufwand im Vergleich 
zu KAFO /SCO .  
3. Bestimmung der Sicherheit der Patienten bei der 
Durchführung verschiedener ambulanter Aktivitäten unter der Verwendung von C -Brace  im Vergleich zu KAFO /SCO . 
4. Bestimmung der Lebensqualität und der Re integration in 
normal e Lebensumstände unter der Verwendung von C -
Brace  im Ver gleich zu KAFO /SCO . 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 83 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 5. Bestimmung des Umfangs der Behinderung und deren 
Einfluss auf die Produktivität . 
6. Bestimmung der Patientenzufriedenheit und der 
Verwendungsgewohnheit von C -Brac e im Vergleich zu 
KAF O/SCO.  
7. Verringerte Sturzwahrscheinlichkeit bei der Verwendung 
von C -Brace im Vergleich zu KAFO /SCO  
 
Klinische Nachverfol-gung Screening, Baseline 1 und 2 , Visite  1 nach 3 Monaten 
Nutzungsdauer des ersten Prüfprodukts zu Hause, V isite 2 nach 
3 Monaten Nutz ungsdauer des zweit en Prüfprodukts zu Hause  
Anzahl der  Patienten  56 
Einschlusskriterien • Patient wurde mit der Diagnostischen Testorthese (DTO) 
getestet  und zeigte erfolgreich das Potential, C -Brace  
nutzen zu können 
• Patient hat  einen  BBS Wert  < 45  
• Beei nträchtigung der unteren Extremität laut Indikation 
in der Gebrauchsanweisung  
• Vorangegangene aktive und verlässliche Nutzung einer 
unilateralen oder bilateralen Versorgung mit einer KAFO oder SCO in den letzten 3 Monaten vor Einschluss  
• Patient erfüllt die  körperlichen Minimalvoraussetzungen 
für die C -Brace  Versorgung, wie Muskelstatus, 
Gelenkmobilität, Beinachse und Kontrolle der Orthese 
• Der Nutzer erfüllt die körperlichen und geistigen 
Voraussetzungen, um optische, akustische Signale, 
sowie mechanische Vi brationen wahrzunehmen 
• Die bestehende Muskelkraft der Hü ftflexoren und –
extensoren muss die Auslösung der Schwungphase 
ermöglichen (Kompensation durch Verwendung der 
Hüfte ist erlaubt)  
• Patient  erklärt sich bereit, C -Brace  für minde stens 1-2 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 84 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Stunden pro Tag  5 Tage die Woche zu verwenden  
• Patient is t ≥18 Jahre alt  
• Patient ist fähig und willens, unabhängig sein 
Einverständnis zu geben  
• Person is t einverstanden, den Prozeduren innerhalb der 
klinischen Studie Folge  zu leisten  
Ausschlusskriteri en • Patient ist nich t in der Lage, alle Studienbesuche zu 
absol vieren oder ist unwillig /nicht in der Lage, den 
Anweisungen zu folgen  
• Patient war nicht in der Lage die DTO zu nutzen 
• Patient nutzt seine Orthese nicht für mindestens 1 -2 
Stunden pro Tag a n 5 Ta gen pro Wo che 
• Patient mit einem Körpergewicht  > 125 k g 
(eingeschlossen Körpergewicht + schwerstes getragenes 
Objekt ) 
• Patient mit Orthopro these 
• Patient mit Flexion skontra ktur  im Knie - oder Hüftgelenk 
> 10° 
• Patient mit unkontrollierter moderater bis schwerer  
Spastizit ät (moderate Spastizität ist relative 
Kontr aindikation ) 
• Beinlängendifferenz > 15cm  
• Patient mit instabiler neurologischer, kardiovaskulärer 
oder pulmonaler Erkrankung oder Krebs erkrankung 
• Schwangerschaft  
• Patient nutzt  bereits C-Brace  
• Patient  mit b ekanntem S chwindel (Vertigo) oder 
Sturzhistorie, welche nicht in Bezug zur 
Orthesennutzung oder motorischer Behinderung steht  
• Patient ist nicht mit einer  Orthese versorgt  
• Patient is t unfähig, selbständig an ihn ausgehändigte 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 85 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Fragebögen zu beantworten ; Pati enten mit einer 
Beeinträchtigung der oberen Extremitä t dürfen verbal 
antworten 
• Patient nimmt während der geplanten Dauer der Studie 
an bereits einer weiteren klinischen  Studie teil  
• Patient hat bereits an einer früheren C -Brace  Studie 
teilgenom men 
Geplante r Zeitverl auf Geplante Studiendauer : 
First Patient  In: 1 Mrz 2019    
Last Patient  In: 30 Dec 2021  
Last Patient  Out:  31 Mrz 2023   
Prüfleiter  Zentrum  1: Prof. Frank Braatz  
Zentrum  2: Dr. Axel Ruetz   
Zentrum  3: Dr. Bea Hemmen  
Zentrum  4: PD D r. Rüdiger R upp  
Zentrum  5: Jason Weni g, CPO, FAAOP  
Zentrum  6: Tom DiBello, LO, CO, FAAOP  
Zentrum  7: Chris Toelle, LCO, ACM   
Zentrum  8: Eric Weber, LCPO, FAAOP  
Zentrum 9: Dr. Alexander Krebs  
  
Informationen zu zusätzlichen Prüfleitern in 
Addendum_CIP V5_SiteList_201217 . 
 
Studienzentren  Zentru m 1: Göttingen (D) 
Zentrum  2: Koblenz (D)  
Zentrum  3: Hoensbroek (NL)  
Zentrum  4: Heidelberg (D)  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 86 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Zentrum  5: Chicago, IL (USA)  
Zentrum  6: Houston, TX (USA)  
Zentrum  7: Sarasota, FL (USA)  
Zentrum  8: Seattle, WA (USA)  
Zentrum 9: Wien (AT ) 
 
Informationen zu zusät zlichen Studienzentren in 
Addendum_CIPV5_SiteList_201217.  
 
Klinischer  Proje ktm an-
ager  Dr. Marten Jakob  
 
 
 
 
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 87 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 23.3  Appendix III: Example of the p hone  call protocol  
PHONE CALL 1 (1 Month)  
 
***THIS PHONE C ALL HAS TO BE DONE IN THE END OF  MON TH 1  AFTER ASSESSMENT OF READINESS !*** 
• Please remind the patient about the minimum time of use  (1-2 hours, 5 days per week) of the current 
orthosis.  
• Ask the patient some questions a bout adverse events (AE) and device deficie ncies  (DD) . 
• Remind the patient t o call the investigator immediately in the case of malfunctions, falls or other limit-
ing events.  
• Remind the patient to document any falls and near falls as well as unexpected behavior of the 
current orthosis in the patient  diary  and to bring the diary at e ach visit.  
• If you need more space for your documentation please use page 8- 9. 
 
Please specify the use of the current orthosis in day(s)/week and the hour(s)/day:  
 
Which orthosis (es) have y ou been using? (Check all that apply)  |__|  C-Brace  |__|  KAFO  
Time using the orthosis (es):  |__|
 day(s)/
week  |__|
 day(s)/
week  
|__|__|
 hour(s)/
day |__|__|
 hour(s)/
day 
Please specify, if the patient uses the curr ent orthosis ≤ 1 hour/day  or < 5 days a week:   
 _______________________________________________________________________________________  
 _______________________________________________________________________________________  
 _______________________________________________________________________________________  
  
 
 
Did you have any health im-
pairments in the past |__| YES  |__| NO  If YES, number of 
events:  |__|__|__|  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 88 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 month ?  
 
Ask for adverse events (unto-
ward medical occurrence, un-
intended disease or injury, or 
untoward clinical sign wheth-
er or not related to the device)  If YES, please specify:  
 
 
 
    
 
Please comp lete an Adverse Event CRF for each reported AE.  
Did your current orthosis 
have any malfunctions or other problems in the past 
month ? 
Ask for device deficiencies  |__| YES  |__| NO  If YES, number of events:  |__|_ _|__|  
If YES, please specify:  
   
 
   
 
Please  complete an Adverse Event CRF for each reported DD.  
 
Have you felt unstable in 
the past month ? 
 |__| Yes
  
 
|__| No   
Did your orthosis prevent any falls in the past 
month?  |__| Yes  
 |__| No  If YES:   
 Number of events:  
|__|__|  
Did you have any fal ls in 
the past month ? |__| Yes  
 
|__| No  If YES:   
 
Number of events:  
|__|__|  
 CLIN ICAL  
INVESTIGATION PLAN  Document 
number:  PD-PS00120016A -
001 
Version  
number:  7 
Project name Clinical trial comparing C-Brace to 
KAFO/SCO  Project no.  PS00120016A  
 
 
Otto Bock  Confidential  Page 89 of 89 
Qualitätsmanage ment  Otto Bock Healthcare Products  GmbH  
Bez. FO -622 Version: V1A zu SOP K -1-29-8 
 Did any falls require medi-
cal attention in the past 
month?  |__| Yes  
 |__| No  If YES:   
 
Number of events:  
|__|__|  
Did any falls cause per ma-
nent injury in the past 
month?  |__| Ye s
  
 
|__| No  If YES:   
 Number of events:  
|__|__|  
Did any falls result in 
missed work in the past 
month?  |__| Yes
  
 
|__| No  If YES:   
 
Number of events:  
|__|__|  
 
 
Date of signature  Name  Signature  
|__|__| |__|__| | 2 | 0 | _ |    |  
  D  D    M  M     Y   Y   Y   Y    
 
 
  
 